<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id><journal-id journal-id-type="publisher-id">jcm</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2077-0383</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39274327</article-id><article-id pub-id-type="pmc">11396446</article-id><article-id pub-id-type="doi">10.3390/jcm13175114</article-id><article-id pub-id-type="publisher-id">jcm-13-05114</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Overview of Neuro-Ophthalmic Findings in Leukodystrophies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bettinger</surname><given-names>Charlotte Maria</given-names></name><xref rid="af1-jcm-13-05114" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Dulz</surname><given-names>Simon</given-names></name><xref rid="af2-jcm-13-05114" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Atiskova</surname><given-names>Yevgeniya</given-names></name><xref rid="af2-jcm-13-05114" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0221-8954</contrib-id><name><surname>Guerreiro</surname><given-names>Helena</given-names></name><xref rid="af3-jcm-13-05114" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2556-6804</contrib-id><name><surname>Sch&#xF6;n</surname><given-names>Gerhard</given-names></name><xref rid="af4-jcm-13-05114" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2288-6431</contrib-id><name><surname>Guder</surname><given-names>Philipp</given-names></name><xref rid="af1-jcm-13-05114" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Maier</surname><given-names>Sarah Lena</given-names></name><xref rid="af1-jcm-13-05114" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Denecke</surname><given-names>Jonas</given-names></name><xref rid="af1-jcm-13-05114" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Bley</surname><given-names>Annette E.</given-names></name><xref rid="af1-jcm-13-05114" ref-type="aff">1</xref><xref rid="c1-jcm-13-05114" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Axer</surname><given-names>Hubertus</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jcm-13-05114"><label>1</label>Children&#x2019;s Hospital, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany; <email>charlotte.bettinger@t-online.de</email> (C.M.B.); <email>p.guder@web.de</email> (P.G.); <email>sarah.lena.maier@gmail.com</email> (S.L.M.); <email>j.denecke@uke.de</email> (J.D.)</aff><aff id="af2-jcm-13-05114"><label>2</label>Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany</aff><aff id="af3-jcm-13-05114"><label>3</label>Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany; <email>h.desousa@uke.de</email></aff><aff id="af4-jcm-13-05114"><label>4</label>Center of Experimental Medicine, Institute for Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany; <email>g.schoen@uke.de</email></aff><author-notes><corresp id="c1-jcm-13-05114"><label>*</label>Correspondence: <email>abley@uke.de</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2024</year></pub-date><volume>13</volume><issue>17</issue><elocation-id>5114</elocation-id><history><date date-type="received"><day>09</day><month>7</month><year>2024</year></date><date date-type="rev-recd"><day>10</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2024</year></date></history><permissions><copyright-statement>&#xA9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background:</bold> Leukodystrophies are a group of rare genetic diseases that primarily affect the white matter of the central nervous system. The broad spectrum of metabolic and pathological causes leads to manifestations at any age, most often in childhood and adolescence, and a variety of symptoms. Leukodystrophies are usually progressive, resulting in severe disabilities and premature death. Progressive visual impairment is a common symptom. Currently, no overview of the manifold neuro-ophthalmologic manifestations and visual impact of leukodystrophies exists. <bold>Methods:</bold> Data from 217 patients in the Hamburg leukodystrophy cohort were analyzed retrospectively for neuro-ophthalmologic manifestations, age of disease onset, and magnetic resonance imaging, visual evoked potential, and optical coherence tomography findings and were compared with data from the literature. <bold>Results:</bold> In total, 68% of the patients suffered from neuro-ophthalmologic symptoms, such as optic atrophy, visual neglect, strabismus, and nystagmus. Depending on the type of leukodystrophy, neuro-ophthalmologic symptoms occurred early or late during the course of the disease. Magnetic resonance imaging scans revealed pathologic alterations in the visual tract that were temporally correlated with symptoms. <bold>Conclusions:</bold> The first optical coherence tomography findings in Krabbe disease and metachromatic leukodystrophy allow retinal assessments. Comprehensive literature research supports the results of this first overview of neuro-ophthalmologic findings in leukodystrophies.</p></abstract><kwd-group><kwd>leukodystrophy</kwd><kwd>white matter disorder</kwd><kwd>eye movement disorder</kwd><kwd>optic atrophy</kwd><kwd>neuro-ophthalmologic symptoms</kwd><kwd>visual impairment</kwd></kwd-group><funding-group><award-group><funding-source>non-profit association Freundeskreis UKE f&#xFC;r Kinder mit Demenz e.V.</funding-source></award-group><funding-statement>This research was funded by the support of the non-profit association Freundeskreis UKE f&#xFC;r Kinder mit Demenz e.V. (<uri xlink:href="https://fk-kindermitdemenz.de">https://fk-kindermitdemenz.de</uri>) accessed on 15 January 2022.</funding-statement></funding-group></article-meta></front>
  <body>
    <sec sec-type="intro" id="sec1-jcm-13-05114">
      <title>1. Introduction</title>
      <p>Leukodystrophies (LDs) are a group of rare genetic neurodegenerative diseases characterized by a predominant involvement of the white matter of the central nervous system (CNS) [<xref rid="B1-jcm-13-05114" ref-type="bibr">1</xref>,<xref rid="B2-jcm-13-05114" ref-type="bibr">2</xref>,<xref rid="B3-jcm-13-05114" ref-type="bibr">3</xref>]. All structural components of the white matter can be affected, including oligodendrocytes, astrocytes, microglia, axons, and blood vessels [<xref rid="B3-jcm-13-05114" ref-type="bibr">3</xref>,<xref rid="B4-jcm-13-05114" ref-type="bibr">4</xref>,<xref rid="B5-jcm-13-05114" ref-type="bibr">5</xref>], resulting in dysfunctional synthesis and maintenance of myelin [<xref rid="B1-jcm-13-05114" ref-type="bibr">1</xref>,<xref rid="B6-jcm-13-05114" ref-type="bibr">6</xref>]. Hypomyelinating and demyelinating forms are distinguished according to myelin presentation over time [<xref rid="B2-jcm-13-05114" ref-type="bibr">2</xref>,<xref rid="B5-jcm-13-05114" ref-type="bibr">5</xref>,<xref rid="B7-jcm-13-05114" ref-type="bibr">7</xref>].</p>
      <p>Hypomyelinating leukodystrophies are usually caused by delayed and/or insufficient formation of myelin [<xref rid="B2-jcm-13-05114" ref-type="bibr">2</xref>,<xref rid="B8-jcm-13-05114" ref-type="bibr">8</xref>,<xref rid="B9-jcm-13-05114" ref-type="bibr">9</xref>]. A typical hypomyelinating leukodystrophy is Pelizaeus&#x2013;Merzbacher disease (PMD), and the appearance of the first symptoms occurs early after birth with developmental delay and nystagmus [<xref rid="B2-jcm-13-05114" ref-type="bibr">2</xref>].</p>
      <p>In demyelinating leukodystrophies, normal appearing myelin formation is followed by a loss of myelin, which leads to symptoms [<xref rid="B2-jcm-13-05114" ref-type="bibr">2</xref>,<xref rid="B10-jcm-13-05114" ref-type="bibr">10</xref>]. Classic demyelinating leukodystrophies are metachromatic leukodystrophy (MLD) and Krabbe disease (KD). In MLD, reduced activity of the enzyme arylsulfatase A leads to an accumulation of sulfatides in the central and peripheral nervous system, resulting in demyelination [<xref rid="B11-jcm-13-05114" ref-type="bibr">11</xref>,<xref rid="B12-jcm-13-05114" ref-type="bibr">12</xref>].</p>
      <p>Clinical onset may occur at any age, from prenatal life to senescence [<xref rid="B5-jcm-13-05114" ref-type="bibr">5</xref>,<xref rid="B7-jcm-13-05114" ref-type="bibr">7</xref>], although many forms begin in infancy and affect clinically inconspicuous children until symptom onset [<xref rid="B5-jcm-13-05114" ref-type="bibr">5</xref>,<xref rid="B7-jcm-13-05114" ref-type="bibr">7</xref>]. Leukodystrophies are caused by different underlying pathomechanisms and lead to a broad spectrum of clinical symptoms. The clinical course is usually progressive, with extensive loss of motor and mental abilities, often leading to helplessness and premature death [<xref rid="B1-jcm-13-05114" ref-type="bibr">1</xref>,<xref rid="B2-jcm-13-05114" ref-type="bibr">2</xref>]. Initial symptoms often include an arrest of motor or cognitive development followed by further deterioration and regression. The most common neurological findings include motor deficits, which often manifest with a delay in reaching motor milestones [<xref rid="B6-jcm-13-05114" ref-type="bibr">6</xref>,<xref rid="B13-jcm-13-05114" ref-type="bibr">13</xref>,<xref rid="B14-jcm-13-05114" ref-type="bibr">14</xref>]. Cognition is often affected during the course of the disease, especially in older patients, but deterioration of cognitive functions may also occur at disease onset. However, milder forms have also been described and are characterized by longer intervals of symptom stability or even improvement [<xref rid="B2-jcm-13-05114" ref-type="bibr">2</xref>]. Most leukodystrophies are inherited in an autosomal recessive manner [<xref rid="B6-jcm-13-05114" ref-type="bibr">6</xref>,<xref rid="B15-jcm-13-05114" ref-type="bibr">15</xref>], although other modes of inheritance exist (autosomal dominant or X-linked) [<xref rid="B15-jcm-13-05114" ref-type="bibr">15</xref>].</p>
      <p>Neurodegenerative diseases are often associated with ocular and optic tract involvement [<xref rid="B16-jcm-13-05114" ref-type="bibr">16</xref>,<xref rid="B17-jcm-13-05114" ref-type="bibr">17</xref>,<xref rid="B18-jcm-13-05114" ref-type="bibr">18</xref>,<xref rid="B19-jcm-13-05114" ref-type="bibr">19</xref>]. Various manifestations range from the anterior eye, as noted in patients with cerebrotendinous xanthomatosis (CTX), who develop cataracts [<xref rid="B20-jcm-13-05114" ref-type="bibr">20</xref>] via myopia in 4H syndrome to optic atrophy in various leukodystrophies [<xref rid="B21-jcm-13-05114" ref-type="bibr">21</xref>].</p>
      <p>Although ocular involvement has been described in numerous single reports of leukodystrophies [<xref rid="B15-jcm-13-05114" ref-type="bibr">15</xref>], no broad observation of a large cohort of multiple leukodystrophies has been attempted thus far. A better understanding of visual impairment in leukodystrophy patients may have an impact on the clinical understanding of these diseases, may even facilitate earlier diagnosis [<xref rid="B15-jcm-13-05114" ref-type="bibr">15</xref>], and may help to identify novel outcome measures in clinical trials.</p>
      <p>Herein, we analyzed different neuro-ophthalmologic symptoms (NOSs) and correlated them with the presence of leukodystrophy and findings in the brain on MRI. We show the first findings of retinal nerve fiber layer imaging (RNFL) performed by optical coherence tomography (OCT) and the potential of this noninvasive imaging method for quantifying extracerebral neuronal tissue.</p>
    </sec>
    <sec id="sec2-jcm-13-05114">
      <title>2. Materials and Methods</title>
      <sec id="sec2dot1-jcm-13-05114">
        <title>2.1. Data Extraction</title>
        <p>The data of 349 patients with leukodystrophies were screened. The data of 217 patients with genetically and/or biochemically confirmed diagnoses of leukodystrophy from the Hamburg leukodystrophy cohort (HLC), Department of Pediatrics at the University Medical Center Hamburg-Eppendorf, Germany, who met the data protection criteria were analyzed retrospectively (informed consent according to PV3782, Ethics Committee of the Medical Association of Hamburg, Hamburg, Germany). The analyzed data records from international as well as German patients were anonymized and processed according to applicable regulations. The defined secondary outcome variables were age, sex, age at symptom onset, type of leukodystrophy, and survival.</p>
        <p>For X-linked adrenoleukodystrophy (X-ALD) patients, only male patients of all ages were analyzed. Females with X-ALD were listed as others. For some analyses, LDs were grouped into demyelinating and hypomyelinating LDs. The following LDs were identified under demyelinating conditions: MLD, X-ALD, KD, Canavan disease (CD), Alexander disease (AxD), vanishing white matter disease (VWM), Aicardi&#x2013;Gouti&#xE8;res syndrome (AGS), and megalencephalic leukoencephalopathy with subcortical cysts (MLC). Under hypomyelinating LDs, we summarized the following: PMD and other less frequent leukodystrophies, such as 4H syndrome and X-linked hypomyelination with spondylometaphyseal dysplasia (H-SMD).</p>
        <p>Clinical status was assessed using a retrospective review of neurological evaluations, neurodevelopmental assessments, and ophthalmological evaluations. The following neuro-ophthalmologic symptoms were defined as primary outcome variables, including the onset of the different neuro-ophthalmologic symptoms:<list list-type="simple"><list-item><label>-</label><p>visual function (e.g., reduced visual acuity, contrast sensitivity, color discrimination, peripheral vision, and higher order visual processing);</p></list-item><list-item><label>-</label><p>eye movement disorders (EMD) (e.g., nystagmus, strabismus that was defined as any heterotropia at near and/or distance fixation);</p></list-item><list-item><label>-</label><p>fixational eye movement disorders (FEMD) (e.g., no ability to fix and follow or track objects);</p></list-item><list-item><label>-</label><p>pupillary light reflex (defined as either absent, delayed, or slowed); and</p></list-item><list-item><label>-</label><p>anterior and periocular segment findings (e.g., cataracts, ptosis, infections of the eye) and posterior segment findings (e.g., optic atrophy).</p></list-item></list>
Normal as well as pathologic results were recorded.</p>
      </sec>
      <sec id="sec2dot2-jcm-13-05114">
        <title>2.2. MRI Analysis</title>
        <p>MRI scans of patients with pathological neuroophthalmological findings were analyzed within a maximum of 1.5 years before or after the reported onset of neuro-ophthalmologic symptoms. T1W and T2W images as well as fluid-attenuated inversion recovery (FLAIR) images in the transverse and sagittal planes were used for the analysis. Brain MR images were acquired at different centers using numerous different scanners and distinct imaging protocols. Every examination included basic MRI sequences, which were used for review. Two independent experienced raters (HG and AB) evaluated these sequences with special attention to the visual tract, which consists of the optic nerve, the optic chiasm, the optic tract, the lateral geniculate nucleus, and the visual cortex in the occipital lobes [<xref rid="B22-jcm-13-05114" ref-type="bibr">22</xref>]. Signal abnormalities were identified and recorded.</p>
      </sec>
      <sec id="sec2dot3-jcm-13-05114">
        <title>2.3. Optical Coherence Tomography and Retinal Nerve Fiber Measurement</title>
        <p>OCT analysis was performed with a swept-source optical coherence tomography (SS-OCT) instrument (Topcon DRI OCT Triton Plus, Topcon Medical Inc., Tokyo, Japan). A circular peripapillary scan was performed in each eye, and retinal nerve fiber (RNFL) measurements (&#x3BC;m) were extracted from ImageNet 6 software (Topcon Medical Inc., Tokyo, Japan). One experienced rater (SD) evaluated the available OCT scans.</p>
      </sec>
      <sec id="sec2dot4-jcm-13-05114">
        <title>2.4. Visual Evoked Potential (VEP)</title>
        <p>The results of the VEP examinations of the patients&#x2019; records were analyzed. If VEP was performed outside of our clinic, no information on the examination protocol was available. VEP findings were recorded and classified as &#x201C;pathological&#x201D; or &#x201C;normal&#x201D; without further specification. For simplification a pathological VEP was considered as neuro-ophthalmologic symptom. VEP examinations that were performed at our institution were performed using RetiPort (Roland Consult Stasche &amp; Finger GmbH, Brandenburg an der Havel, Germany). For the device settings for pattern reversal VEP, the screen illumination was set to 50 cd/m<sup>2</sup>, the contrast was set to 100%, the pattern turnover ratio was set to 2/sec, and the sweep time was set to 300 ms. For the filter settings, the subfilter was set to 1 Hz. In the case of flash VEP, a 3 cd/s/m<sup>&#x2212;2</sup> flash stimulus with a flash rate of 1 Hz was used. All electrodes were applied according to the ISCEV guidelines [<xref rid="B23-jcm-13-05114" ref-type="bibr">23</xref>].</p>
      </sec>
      <sec id="sec2dot5-jcm-13-05114">
        <title>2.5. Literature Review</title>
        <p>To compare our data with data from the literature, a systematic analysis of the literature was conducted. The search strategy for the biomedical database MEDLINE via PubMed used a combination of key words (MeSH-terms) and free text (last searched May 15, 2022; the search strategy was as follows: ((&#x201C;Leukodystrophy&#x201D;[MeSh]) OR (&#x201C;Leukoencephalopathies&#x201D; [MeSh]) OR (&#x201C;MLD&#x201D;) OR (&#x201C;Leukodystrophy, Metachromatic&#x201D; [MeSh]) OR (&#x201C;Canavan disease&#x201D; [MeSh]) OR (&#x201C;Krabbe disease&#x201D; [MeSh]) OR (&#x201C;Leukodystrophy, Globoid Cell&#x201D; [MeSh]) OR (&#x201C;Adrenoleukodystrophy&#x201D; [MeSh]) OR (&#x201C;ALD&#x201D;) OR (&#x201C;PMD&#x201D;) OR (&#x201C;Pelizaeus&#x2013;Merzbacher disease&#x201D; [MeSh]) OR (&#x201C;VWM&#x201D;) OR (&#x201C;Vanishing white matter&#x201D;) OR (&#x201C;Alexander disease&#x201D; [MeSh]) OR (&#x201C;Aicardi&#x2013;Gouti&#xE8;res syndrome&#x201D; [MeSh]) OR (&#x201C;AGS&#x201D;) OR (&#x201C;MLC&#x201D;) OR (&#x201C;Megaleukoencephalopathy&#x201D; [MeSh])) AND ((&#x201C;Nystagmus, Pathologic&#x201D;[MeSh]) OR (&#x201C;Nystagmus, Congenital&#x201D; [MeSh]) OR (&#x201C;Optic Atrophy&#x201D; [MeSh]) OR (&#x201C;Strabismus&#x201D; [MeSh]) OR (&#x201C;Visual inattention&#x201D;) OR (&#x201C;Pupil disorders&#x201D; [MeSh]) OR (&#x201C;Eye movement&#x201D; [MeSh]) OR (&#x201C;Fixation, Ocular&#x201D; [MeSh]) OR (&#x201C;Visual Fields&#x201D; [MeSh]) OR (&#x201C;Vision, Ocular&#x201D; [MeSh]) OR (&#x201C;Pupillary reaction&#x201D;) OR (&#x201C;Pupillary response&#x201D;) OR (&#x201C;VEP&#x201D;) OR (&#x201C;Visual evoked potentials&#x201D; [MeSh])).</p>
        <p>The following databases were searched using free text combinations: EMBASE, ISI Web of Knowledge, Cochrane Central Register of Controlled Trials (CENTRAL), BioMed Central, and ScienceDirect (last searched 15 May 2022). No language restrictions were imposed. We additionally screened clinical trial registries, including WHO International Clinical Trials Registry and ClinicalTrials.gov, as well as the reference lists of the full texts of potentially relevant studies and review articles (last searched 15 May 2021). We searched for prospective and retrospective longitudinal observational studies investigating the association between leukodystrophies and the neuro-ophthalmologic symptoms. We also analyzed reviews, editorials, and commentaries. CB screened the identified articles and reviewed the full texts of the potentially relevant references. CB performed the data extraction and analysis. All references were managed and stored in EndNote 20 [<xref rid="B24-jcm-13-05114" ref-type="bibr">24</xref>,<xref rid="B25-jcm-13-05114" ref-type="bibr">25</xref>,<xref rid="B26-jcm-13-05114" ref-type="bibr">26</xref>,<xref rid="B27-jcm-13-05114" ref-type="bibr">27</xref>,<xref rid="B28-jcm-13-05114" ref-type="bibr">28</xref>,<xref rid="B29-jcm-13-05114" ref-type="bibr">29</xref>,<xref rid="B30-jcm-13-05114" ref-type="bibr">30</xref>,<xref rid="B31-jcm-13-05114" ref-type="bibr">31</xref>,<xref rid="B32-jcm-13-05114" ref-type="bibr">32</xref>,<xref rid="B33-jcm-13-05114" ref-type="bibr">33</xref>,<xref rid="B34-jcm-13-05114" ref-type="bibr">34</xref>,<xref rid="B35-jcm-13-05114" ref-type="bibr">35</xref>,<xref rid="B36-jcm-13-05114" ref-type="bibr">36</xref>,<xref rid="B37-jcm-13-05114" ref-type="bibr">37</xref>,<xref rid="B38-jcm-13-05114" ref-type="bibr">38</xref>,<xref rid="B39-jcm-13-05114" ref-type="bibr">39</xref>,<xref rid="B40-jcm-13-05114" ref-type="bibr">40</xref>,<xref rid="B41-jcm-13-05114" ref-type="bibr">41</xref>,<xref rid="B42-jcm-13-05114" ref-type="bibr">42</xref>,<xref rid="B43-jcm-13-05114" ref-type="bibr">43</xref>,<xref rid="B44-jcm-13-05114" ref-type="bibr">44</xref>,<xref rid="B45-jcm-13-05114" ref-type="bibr">45</xref>,<xref rid="B46-jcm-13-05114" ref-type="bibr">46</xref>,<xref rid="B47-jcm-13-05114" ref-type="bibr">47</xref>,<xref rid="B48-jcm-13-05114" ref-type="bibr">48</xref>,<xref rid="B49-jcm-13-05114" ref-type="bibr">49</xref>,<xref rid="B50-jcm-13-05114" ref-type="bibr">50</xref>,<xref rid="B51-jcm-13-05114" ref-type="bibr">51</xref>,<xref rid="B52-jcm-13-05114" ref-type="bibr">52</xref>,<xref rid="B53-jcm-13-05114" ref-type="bibr">53</xref>,<xref rid="B54-jcm-13-05114" ref-type="bibr">54</xref>,<xref rid="B55-jcm-13-05114" ref-type="bibr">55</xref>,<xref rid="B56-jcm-13-05114" ref-type="bibr">56</xref>,<xref rid="B57-jcm-13-05114" ref-type="bibr">57</xref>,<xref rid="B58-jcm-13-05114" ref-type="bibr">58</xref>,<xref rid="B59-jcm-13-05114" ref-type="bibr">59</xref>,<xref rid="B60-jcm-13-05114" ref-type="bibr">60</xref>,<xref rid="B61-jcm-13-05114" ref-type="bibr">61</xref>,<xref rid="B62-jcm-13-05114" ref-type="bibr">62</xref>,<xref rid="B63-jcm-13-05114" ref-type="bibr">63</xref>,<xref rid="B64-jcm-13-05114" ref-type="bibr">64</xref>,<xref rid="B65-jcm-13-05114" ref-type="bibr">65</xref>,<xref rid="B66-jcm-13-05114" ref-type="bibr">66</xref>,<xref rid="B67-jcm-13-05114" ref-type="bibr">67</xref>,<xref rid="B68-jcm-13-05114" ref-type="bibr">68</xref>,<xref rid="B69-jcm-13-05114" ref-type="bibr">69</xref>,<xref rid="B70-jcm-13-05114" ref-type="bibr">70</xref>,<xref rid="B71-jcm-13-05114" ref-type="bibr">71</xref>,<xref rid="B72-jcm-13-05114" ref-type="bibr">72</xref>,<xref rid="B73-jcm-13-05114" ref-type="bibr">73</xref>,<xref rid="B74-jcm-13-05114" ref-type="bibr">74</xref>,<xref rid="B75-jcm-13-05114" ref-type="bibr">75</xref>,<xref rid="B76-jcm-13-05114" ref-type="bibr">76</xref>,<xref rid="B77-jcm-13-05114" ref-type="bibr">77</xref>,<xref rid="B78-jcm-13-05114" ref-type="bibr">78</xref>,<xref rid="B79-jcm-13-05114" ref-type="bibr">79</xref>,<xref rid="B80-jcm-13-05114" ref-type="bibr">80</xref>,<xref rid="B81-jcm-13-05114" ref-type="bibr">81</xref>,<xref rid="B82-jcm-13-05114" ref-type="bibr">82</xref>,<xref rid="B83-jcm-13-05114" ref-type="bibr">83</xref>,<xref rid="B84-jcm-13-05114" ref-type="bibr">84</xref>,<xref rid="B85-jcm-13-05114" ref-type="bibr">85</xref>,<xref rid="B86-jcm-13-05114" ref-type="bibr">86</xref>,<xref rid="B87-jcm-13-05114" ref-type="bibr">87</xref>,<xref rid="B88-jcm-13-05114" ref-type="bibr">88</xref>,<xref rid="B89-jcm-13-05114" ref-type="bibr">89</xref>,<xref rid="B90-jcm-13-05114" ref-type="bibr">90</xref>,<xref rid="B91-jcm-13-05114" ref-type="bibr">91</xref>,<xref rid="B92-jcm-13-05114" ref-type="bibr">92</xref>,<xref rid="B93-jcm-13-05114" ref-type="bibr">93</xref>,<xref rid="B94-jcm-13-05114" ref-type="bibr">94</xref>,<xref rid="B95-jcm-13-05114" ref-type="bibr">95</xref>,<xref rid="B96-jcm-13-05114" ref-type="bibr">96</xref>,<xref rid="B97-jcm-13-05114" ref-type="bibr">97</xref>,<xref rid="B98-jcm-13-05114" ref-type="bibr">98</xref>,<xref rid="B99-jcm-13-05114" ref-type="bibr">99</xref>,<xref rid="B100-jcm-13-05114" ref-type="bibr">100</xref>,<xref rid="B101-jcm-13-05114" ref-type="bibr">101</xref>,<xref rid="B102-jcm-13-05114" ref-type="bibr">102</xref>,<xref rid="B103-jcm-13-05114" ref-type="bibr">103</xref>,<xref rid="B104-jcm-13-05114" ref-type="bibr">104</xref>,<xref rid="B105-jcm-13-05114" ref-type="bibr">105</xref>,<xref rid="B106-jcm-13-05114" ref-type="bibr">106</xref>,<xref rid="B107-jcm-13-05114" ref-type="bibr">107</xref>,<xref rid="B108-jcm-13-05114" ref-type="bibr">108</xref>,<xref rid="B109-jcm-13-05114" ref-type="bibr">109</xref>,<xref rid="B110-jcm-13-05114" ref-type="bibr">110</xref>,<xref rid="B111-jcm-13-05114" ref-type="bibr">111</xref>,<xref rid="B112-jcm-13-05114" ref-type="bibr">112</xref>,<xref rid="B113-jcm-13-05114" ref-type="bibr">113</xref>,<xref rid="B114-jcm-13-05114" ref-type="bibr">114</xref>,<xref rid="B115-jcm-13-05114" ref-type="bibr">115</xref>,<xref rid="B116-jcm-13-05114" ref-type="bibr">116</xref>,<xref rid="B117-jcm-13-05114" ref-type="bibr">117</xref>,<xref rid="B118-jcm-13-05114" ref-type="bibr">118</xref>,<xref rid="B119-jcm-13-05114" ref-type="bibr">119</xref>,<xref rid="B120-jcm-13-05114" ref-type="bibr">120</xref>,<xref rid="B121-jcm-13-05114" ref-type="bibr">121</xref>,<xref rid="B122-jcm-13-05114" ref-type="bibr">122</xref>,<xref rid="B123-jcm-13-05114" ref-type="bibr">123</xref>,<xref rid="B124-jcm-13-05114" ref-type="bibr">124</xref>,<xref rid="B125-jcm-13-05114" ref-type="bibr">125</xref>,<xref rid="B126-jcm-13-05114" ref-type="bibr">126</xref>,<xref rid="B127-jcm-13-05114" ref-type="bibr">127</xref>,<xref rid="B128-jcm-13-05114" ref-type="bibr">128</xref>,<xref rid="B129-jcm-13-05114" ref-type="bibr">129</xref>,<xref rid="B130-jcm-13-05114" ref-type="bibr">130</xref>,<xref rid="B131-jcm-13-05114" ref-type="bibr">131</xref>,<xref rid="B132-jcm-13-05114" ref-type="bibr">132</xref>]. The literature search (Lit.) identified 529 possibly relevant references. Of these, 268 references were included for full-text evaluation. In total, we incorporated data from 168 publications into the analysis. <xref rid="jcm-13-05114-f001" ref-type="fig">Figure 1</xref> provides an overview of the study selection process according to the PRISMA guidelines [<xref rid="B133-jcm-13-05114" ref-type="bibr">133</xref>]. The flowchart shows the number of studies identified, excluded, and included, as well as the reasons for the exclusions.</p>
      </sec>
      <sec id="sec2dot6-jcm-13-05114">
        <title>2.6. Data Analysis</title>
        <p>The data were analyzed in a Microsoft Excel Version 16.77 (23091003) spreadsheet. As descriptive statistics, arithmetic means and standard deviations are reported for the metric characteristics and counts, and proportions are reported for categorical variables.</p>
        <p>For the analysis of time to symptom onset (FEMD, EMD, and visual function), the time between diagnosis and symptom onset was used. For patients without symptoms, the time between diagnosis and the last hospital visit was used. Statistical analyses were performed by the UKE Institute of Biometry and Statistics (GS) using the program R&#xB9; (Version 3.4.3).</p>
      </sec>
    </sec>
    <sec sec-type="results" id="sec3-jcm-13-05114">
      <title>3. Results</title>
      <sec id="sec3dot1-jcm-13-05114">
        <title>3.1. Patient Characteristics</title>
        <p>The data of 217 patients with various leukodystrophies in the Hamburg leukodystrophy cohort (HLC) and 1153 patients from the literature search (LCC) were analyzed. The median age of disease onset of HLC patients was 7 months, varying from leukodystrophies with an early onset of 1 month as noted for PMD to leukodystrophies with a later onset as noted for X-ALD (median age of onset of 94 months). In the literature, the median age of onset of the disease was 6 months, ranging from 2 months for PMD to 83 months for X-ALD. A balanced sex distribution was observed in both cohorts, excluding patients with X-linked inherited leukodystrophies such as PMD, X-ALD, and H-SMD. Neuro-ophthalmologic symptoms occurred in 68% of HLC and 76% of LLC patients during the course of the disease. The occurrence of neuro-ophthalmologic symptoms depended on the type of leukodystrophy. In the HLC, patients with PMD (100%) and CD (100%) were most frequently affected by neuro-ophthalmologic symptoms, a tendency that was also observed in the LLC (PMD 98%, CD 83%). HLC patients with AxD (30%) and MLD (42%) were less frequently affected by neuro-ophthalmologic symptoms. In the LLC, the lowest prevalence was identified in patients with VWM (29%) and MLD (32%). Most neuro-ophthalmologic findings were progressive in patients that were observed over an extended period. Follow up time spans were 0&#x2013;39 years with a median of 4.2 years (some patients only presented to us once).</p>
        <p>An overview of the age at onset of the disease, the occurrence of neuro-ophthalmologic symptoms, and patient sex for different leukodystrophies is shown in <xref rid="jcm-13-05114-t001" ref-type="table">Table 1</xref>.</p>
      </sec>
      <sec id="sec3dot2-jcm-13-05114">
        <title>3.2. Neuro-Ophthalmologic Disease Manifestations</title>
        <p>The majority of leukodystrophy patients (68%) developed one or more than one (total sum of 366 neuro-ophthalmologic findings in the HLC) neuro-ophthalmologic symptoms during the course of the disease. Neuro-ophthalmologic symptoms occur early or late during the course of the disease. On average, if a leukodystrophy patient became symptomatic, the first description of neuro-ophthalmologic symptoms occurred within 6 months (range from 0 months to 33 years). Neuro-ophthalmologic symptoms were reported to be the first symptom of leukodystrophy in 26% of HLC patients (<italic toggle="yes">n</italic> = 38). In 8% (<italic toggle="yes">n</italic> = 12) of the patients, neuro-ophthalmologic symptoms were even reported to be present at birth, mainly in patients with PMD (<italic toggle="yes">n</italic> = 7) and CD (<italic toggle="yes">n</italic> = 4). The first neuro-ophthalmologic symptoms were reported to occur in the same month as disease onset in PMD and one month after disease onset in CD. Patients with AGS or KD were reported to suffer from neuro-ophthalmologic symptoms early in the course of the disease (4 and 5 months after disease onset, respectively). In those with X-ALD, neuro-ophthalmologic symptoms occurred 9 months after the onset of the disease. However, in other leukodystrophies, neuro-ophthalmologic symptoms were reported to occur rather late during the course of the disease, as were MLD (median 31 months), AxD (median 44 months), VWM (median 86 months) and MLC (median 100 months).</p>
        <p>We differentiated neuro-ophthalmologic symptoms in all leukodystrophies by the kind of neuro-ophthalmic symptom. The most common were eye movement disorders (EMDs) in 30% and fixational eye movement disorders (FEMDs) in 15%, followed by posterior segment findings in 13%. The frequencies of all analyzed neuro-ophthalmologic symptoms are listed in <xref rid="jcm-13-05114-t002" ref-type="table">Table 2</xref>.</p>
        <p>In total, 1057 pathological findings were extracted from 1153 patients in the literature (LLC). As noted in the HLC, the most common findings were eye movement disorders (60%), followed by impaired visual function (21%) and posterior segment findings such as optic atrophy (14%), as shown in <xref rid="jcm-13-05114-t002" ref-type="table">Table 2</xref>.</p>
        <p>The neuro-ophthalmologic symptoms were differentiated according to the type of leukodystrophy and the type of the neuro-ophthalmologic symptom. Frequencies of specific neuro-ophthalmologic symptoms in the HLC and LLC are shown in <xref rid="jcm-13-05114-t003" ref-type="table">Table 3</xref>.</p>
        <sec id="sec3dot2dot1-jcm-13-05114">
          <title>3.2.1. EMD Nystagmus as an Early Sign of Hypomyelinating Leukodystrophies</title>
          <p>The eye movement disorder nystagmus was the most common neuro-ophthalmologic symptoms in our analyzed leukodystrophy patients (28%). It occurred most frequently in PMD patients (100%), followed by CD patients (62%). The frequency of nystagmus is shown in <xref rid="jcm-13-05114-t003" ref-type="table">Table 3</xref>. In 28% of patients, nystagmus was the first clinical sign of disease, and it was congenital in 18%. Considering only hypomyelinating forms of leukodystrophies (<italic toggle="yes">n</italic> = 26), nystagmus occurred in 77% of patients with a median of 0 months after disease onset (range 0 months to 20 years). In the demyelinating group (<italic toggle="yes">n</italic> = 191), only 21% of patients exhibited nystagmus with a median of 5 months after disease onset (range 0 months to 13 years). In 22% of patients, the nystagmus disappeared completely during the course of the disease, with a median age of 29 months (range 7 months to 15 years) after the first onset of nystagmus, regardless of the type of leukodystrophy. For 72% (569/790) of all LLC patients, nystagmus was reported. Among patients with nystagmus, 86% had a hypomyelinating form of leukodystrophy, and 14% had a demyelinating form of leukodystrophy.</p>
        </sec>
        <sec id="sec3dot2dot2-jcm-13-05114">
          <title>3.2.2. EMD Strabismus</title>
          <p>Strabismus was diagnosed in 18% of HLC patients, with a median age of onset of 8 months (range 0 months to 33 years) after disease onset. Patients with PMD (31%) were affected most frequently, followed by those with CD (26%) and other LDs, as shown in <xref rid="jcm-13-05114-t003" ref-type="table">Table 3</xref>. In terms of hypomyelinating forms, 42% of patients showed strabismus with a median time span of 12 months after disease onset. In terms of demyelinating forms, 15% of patients developed strabismus with a median time span of 6 months after disease onset. Within the LLC, a total of 34% (68/202) of patients developed strabismus. The distribution of strabismus in the different forms of leukodystrophies is listed in <xref rid="jcm-13-05114-t003" ref-type="table">Table 3</xref>. Among these patients who developed a strabismus, 9% had hypomyelination, and 91% had a demyelinating form of leukodystrophy.</p>
        </sec>
        <sec id="sec3dot2dot3-jcm-13-05114">
          <title>3.2.3. Fixational Eye Movement Disorders (FEMD)</title>
          <p>Twenty-five percent of HLC patients developed fixational eye movement disorders, with a median age of onset of 7 months (range 0 to 326) after disease onset. Patients with CD (56%) and AGS (44%) were affected most commonly. In LCC, 69% (24/35) of the patients were described to have a fixational eye movement disorder (further details in <xref rid="jcm-13-05114-t003" ref-type="table">Table 3</xref>).</p>
        </sec>
        <sec id="sec3dot2dot4-jcm-13-05114">
          <title>3.2.4. Visual Function</title>
          <p>Impaired visual function was observed in 11% of all HLC patients, with a median age of onset of 18 months (range 0 to 432 months) after disease onset. Visual function impairment was most commonly reported in X-ALD (27%) and CD (21%) and less frequently in VWM (8%) and other forms of leukodystrophies (further details in <xref rid="jcm-13-05114-t003" ref-type="table">Table 3</xref>). In the LLC, 53% (223/417) of patients had a deficit in visual function. In detail, of the patients who showed impaired visual function, 63% were patients with demyelinating leukodystrophies, and 29% were patients with hypomyelinating leukodystrophies.</p>
        </sec>
        <sec id="sec3dot2dot5-jcm-13-05114">
          <title>3.2.5. Pupillary Light Reflex</title>
          <p>A pathologic pupillary light reflex was less frequently reported in 14% (<italic toggle="yes">n</italic> = 31) of HLC patients, without major differences in patients with demyelination or hypomyelination. Median age of onset was 35 months (range 0 to 284) after disease onset. In the LLC, 39% (<italic toggle="yes">n</italic> = 28/72) were found to have a pathological light reaction. Further details of the occurrence of a pathological pupillary light reflex in the different forms of leukodystrophies of both cohorts are depicted in <xref rid="jcm-13-05114-t003" ref-type="table">Table 3</xref>.</p>
        </sec>
        <sec id="sec3dot2dot6-jcm-13-05114">
          <title>3.2.6. Anterior and Periocular Segment Findings</title>
          <p>In the HLC, 11% (<italic toggle="yes">n</italic> = 23) had pathological findings of the anterior or periocular segment. The findings were inflammation of the anterior or periocular segment (hordeolum, blepharitis, and conjunctivitis) in 30% (<italic toggle="yes">n</italic> = 7) most frequently in patients with CD (<italic toggle="yes">n</italic> = 3) and MLD (<italic toggle="yes">n</italic> = 2), cataracts in 30% (<italic toggle="yes">n</italic> = 7) of patients with CTX (<italic toggle="yes">n</italic> = 2) and HCC (<italic toggle="yes">n</italic> = 1), and ptosis in 22% (<italic toggle="yes">n</italic> = 5) of patients with MLD (<italic toggle="yes">n</italic> = 2). Sparse LCC data did not allow for sufficient analysis.</p>
        </sec>
        <sec id="sec3dot2dot7-jcm-13-05114">
          <title>3.2.7. Posterior Segment Findings as Optic Atrophy</title>
          <p>Only 14% of HLC patients (<italic toggle="yes">n</italic> = 30) were reported to develop optic atrophy during the progression of the disease, with a median age of onset of 25 months (range 0 to 319 months) after disease onset. Patients with AGS (33%; <italic toggle="yes">n</italic> = 3/9) and PMD (31%, <italic toggle="yes">n</italic> = 4/13) were affected most frequently, followed by those with other LDs, as shown in <xref rid="app1-jcm-13-05114" ref-type="app">Supplemental Table S1</xref>. Patients with hypomyelinating forms (35%; <italic toggle="yes">n</italic> = 9/26) were more often affected than patients with demyelinating forms (11%; <italic toggle="yes">n</italic> = 21/191). Among all patients identified by the literature search, 38% (145/385) developed optic atrophy during the course of the disease. Overall, 14% of patients with optic atrophy had hypomyelinating forms of leukodystrophy, and 86% had demyelinating forms of leukodystrophy.</p>
        </sec>
      </sec>
      <sec id="sec3dot3-jcm-13-05114">
        <title>3.3. VEP Results in Leukodystrophies</title>
        <p>In total, 57 VEP results in 54 HLC symptomatic and pre-symptomatic patients were reported. Thirty-five patients showed pathological VEP findings (65%). A detailed analysis of all LD forms and percentages of pathologic VEP findings is shown in <xref rid="jcm-13-05114-t004" ref-type="table">Table 4</xref>. In the group with hypomyelinating forms of leukodystrophies, pathological VEP findings were noted in 100% (<italic toggle="yes">n</italic> = 8/8) of patients, and in the group with demyelinating forms of leukodystrophies, it was found in 59% (<italic toggle="yes">n</italic> = 27/46) of patients. Patients exhibiting normal VEP findings had a median illness duration of 15 months, whereas those with pathological VEP findings demonstrated a significantly longer median illness duration of 26 months.</p>
        <p>Almost all 35 patients with pathological VEP findings had at least one other neuro-ophthalmologic symptom. In total, the 35 patients with pathological VEP findings had 87 additional neuro-ophthalmologic findings. The most common were EMD (<italic toggle="yes">n</italic> = 29), followed by posterior segment findings (<italic toggle="yes">n</italic> = 16) and FEMD (<italic toggle="yes">n</italic> = 10). Normal VEP findings were initially observed in 22 patients. Three patients (1 MLD, 1 AxD, 1 MLC) developed pathological VEP findings during the course of the disease, leaving 19 patients with normal VEP findings during the observation of AxD (<italic toggle="yes">n</italic> = 2/3), KD (<italic toggle="yes">n</italic> = 3/4), X-ALD (<italic toggle="yes">n</italic> = 3/5), VWM (<italic toggle="yes">n</italic> = 2/4), and MLD (<italic toggle="yes">n</italic> = 8/19) patients. Patients with normal VEP findings had a median disease duration of 15 months.</p>
        <p>In LLC patients, 66% (<italic toggle="yes">n</italic> = 52/79) had pathologic VEP results. Pathological VEP results occurred more frequently in hypomyelinating forms of leukodystrophy (83%; <italic toggle="yes">n</italic> = 15/18) than in demyelinating forms (61%; <italic toggle="yes">n</italic> = 37/61). More details are shown in <xref rid="jcm-13-05114-t004" ref-type="table">Table 4</xref>.</p>
      </sec>
      <sec id="sec3dot4-jcm-13-05114">
        <title>3.4. OCT in Leukodystrophies</title>
        <p>OCT was performed in 10 leukodystrophy patients (3 KD, 2 MLD, 2 X-ALD, 1 MLC, 1 4H syndrome, 1 CTX). The findings of nine patients were available for evaluation. Three patients showed abnormal thinning of the retinal nerve fiber layer on OCT, and six showed no abnormalities. The six patients with normal OCT findings (<xref rid="jcm-13-05114-f002" ref-type="fig">Figure 2</xref>, normal findings in a&#x2013;d) were reported to be either early in their course of the disease or were suffering from a leukodystrophy with a late onset. One of the MLD patients has received an experimental treatment and has been symptom stable for years, and the one patient with proven X-ALD is presymptomatic for ccALD suffering only from Addison&#x2019;s disease.</p>
        <p>Two patients with KD and one patient with 4H syndrome showed abnormal thinning of the retinal nerve fiber layer (RNFL) on OCT (<xref rid="jcm-13-05114-f003" ref-type="fig">Figure 3</xref>). At the time of the OCT examination, optic atrophy was present in all three patients, which was diagnosed by inspection by an ophthalmologist. Neuro-ophthalmologic symptoms were detected in almost all patients with normal OCT results; in detail, two had cataracts, and three had refractive errors.</p>
      </sec>
      <sec id="sec3dot5-jcm-13-05114">
        <title>3.5. MRI Findings Correlate with Neuro-Ophthalmologic Findings</title>
        <p>We analyzed 49 MRI scans of 49 patients for whom cranial MRI was performed 1.5 years before or after the onset of neuro-ophthalmologic symptoms. Patients were affected by the following neuro-ophthalmologic symptoms: EMD (<italic toggle="yes">n</italic> = 23), FEMD (<italic toggle="yes">n</italic> = 29), and pathological pupillary light reflex (<italic toggle="yes">n</italic> = 2). Five patients had two neuro-ophthalmologic symptoms at the time of evaluation. In-depth analysis of the visual tract was performed on T1W, T2W, and FLAIR cranial MR images.</p>
        <p>The majority (<italic toggle="yes">n</italic> = 47/49) exhibited pathologic visual pathway effects on the brain (<xref rid="jcm-13-05114-f004" ref-type="fig">Figure 4</xref>), with effects on the periventricular parietooccipital white matter. Only two patients presented with age-appropriate MR images. Symptoms of these patients were a transient setting-sun phenomenon in an otherwise presymptomatic KD and strabismus in an X-ALD female conductor.</p>
        <p>Myelin involvement of the parieto-occipital white matter and visual pathway was observed in all MRI images. Additional distinct findings were optic nerve kinking (increased tortuosity of the optic nerve) in eight patients (3 CD, 1 KD, 1 PMD, 1 X-ALD, 1 4H-syndrome, 1 Col4a1), optic nerve sheath dilatation/optic disc swelling in seven patients (1 CD, 3 KD, 1 VWM, 1 4H syndrome, 1 GM2) and optic atrophy in one patient (VWM), as shown in <xref rid="jcm-13-05114-f005" ref-type="fig">Figure 5</xref>.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="sec4-jcm-13-05114">
      <title>4. Discussion</title>
      <p>This study describes the occurrence and frequency of different neuro-ophthalmologic symptoms in 217 patients with different leukodystrophies in a leukodystrophy cohort and compares them with data from 1153 patients reported in the literature. We further report the heterogeneity of the occurrence of the neuro-ophthalmologic symptoms in relation to the timing of the first disease symptom in patients with different types of leukodystrophies. We describe the corresponding findings of ophthalmologic and other diagnostic methods, such as MRI, VEP, and OCT. In two patients with Krabbe disease and one patient with 4H syndrome, we report a previously unpublished abnormal thinning of the retinal nerve fiber layer observed in OCT imaging.</p>
      <p>Neuro-ophthalmologic symptoms are common findings in leukodystrophies. In our cohort, 68% of our patients were reported to suffer from neuro-ophthalmologic symptoms, compared to 76% in the literature cohort. The occurrence of neuro-ophthalmologic symptoms was 100% in patients with PMD and CD in our cohort and was also very frequent feature in patients in the literature with PMD (98%) and CD (83%). In 26% of our cohort, neuro-ophthalmologic symptoms were among the first symptoms of the disease, especially in patients suffering from PMD and CD. Hence, the majority of neuro-ophthalmologic symptoms occurs secondarily during the course of the disease. Some symptoms occurred usually earlier in the course of the disease, such as EMD (median nystagmus 0 months and strabismus 8 months after disease onset) and FEMD (median 7 months after disease onset). Other neuro-ophthalmologic symptoms occurred later during the course of the disease as optic atrophy occurred at a median of 25 months after disease onset and pathologic light response at a median of 35 months after disease onset. These finding may support development of specific treatments according to affected functions during the course of the disease.</p>
      <p>Interestingly, we found that the most common neuro-ophthalmologic symptoms in leukodystrophy patients (30% in our cohort, 60% in the literature) were eye movement disorders. Among these patients, nystagmus was most common (54%) and appeared at disease onset in our cohort, predominantly in patients with hypomyelinating leukodystrophies, including PMD, as reported previously [<xref rid="B13-jcm-13-05114" ref-type="bibr">13</xref>]. Nystagmus in general, as an eye movement disorder, may reflect the interruption of visual input, which is important for optimal eye movement [<xref rid="B135-jcm-13-05114" ref-type="bibr">135</xref>]. It is frequently observed in children with cortical and subcortical visual disorders and might be associated with severe visual disturbances and inability to fix and track objects [<xref rid="B136-jcm-13-05114" ref-type="bibr">136</xref>]. Nystagmus is not solely related to neuro-ophthalmic pathologies, but it can also be observed in diseases of the vestibular apparatus or central nervous regions such as those of the brainstem [<xref rid="B137-jcm-13-05114" ref-type="bibr">137</xref>] and as a sequel of intoxications and metabolic disorders [<xref rid="B138-jcm-13-05114" ref-type="bibr">138</xref>]. It is not yet understood why nystagmus occurs predominantly in hypomyelinating forms of leukodystrophies. It is possible that the disruption of early myelinating structures (as for example infratentorial structures) might be related to the higher occurrence.</p>
      <p>The optic tract crosses the brain and is dependent on the degree of myelination. In our patients with hypomyelinating leukodystrophies, 100% of the VEP findings were abnormal, and 83% of the VEP findings in the literature group with hypomyelinating leukodystrophies were abnormal, reflecting insufficient myelination of the optical tract/optic pathway. The occurrence of nystagmus in 100% of our PMD patients appears conclusive with this finding. Interestingly, none of our PMD patients reported suffering from a visual function deficit. Since VEPs reflect the sum of the functions of the retina, the visual pathway, and the processing of visual stimuli by the brain, these findings mainly represent a pathology of the visual pathway or visual cortex in LD [<xref rid="B139-jcm-13-05114" ref-type="bibr">139</xref>]. We hypothesize that nearly all patients with leukodystrophy exhibit pathological VEP during the progression of the illness. Due to their age and disabilities, these patients are usually unable to communicate visual symptoms or participate in standardized tests, so the VEP serves as a surrogate parameter for the duration or stage of the disease [<xref rid="B140-jcm-13-05114" ref-type="bibr">140</xref>].</p>
      <p>It is also not understood why, regardless of whether it is a hypomyelination or a demyelinating form of leukodystrophy, in 22% of HLC patients, the nystagmus disappeared completely over the course of the disease, with a median of 29 months (range 7 months to 15 years) after onset. Patients with hypomyelinating leukodystrophies, such as PMD or 4H syndrome, often gain further developmental milestones over time before a regression is noted. Atrophy is often described to occur after some time, often years, in hypomyelinating leukodystrophies, such as PMD [<xref rid="B141-jcm-13-05114" ref-type="bibr">141</xref>] We assume that this partial, at least functional, maturation may also affect the nystagmus positively.</p>
      <p>In demyelinating leukodystrophies, we rather assume that the initial affection of structures causes neuronal imbalances that lead to the nystagmus. Further degeneration with almost complete loss of myelinated structures and progressive atrophy may affect the symptoms of nystagmus, leading to blindness with regression of nystagmus due to more unspecific oculomotor problems. Further research with prospective assessments, such as ophthalmologic examination, MRI, and VEP, may support elucidation of the pathogenesis of nystagmus in different LDs and in general.</p>
      <p>The second most common eye movement disorder in our cohort was strabismus (18%), with a median onset of 8 months after disease onset. In our cohort, strabismus was most common in hypomyelinating LDs, as in PMD. Forty-two percent of patients showed strabismus with a median time span of 12 months after disease onset. However, in demyelinating forms, 15% of patients developed strabismus with a median time span of 6 months after disease onset. A specific correlation to one or more of the involved neurologic systems that are important for eye movement coordination in the brainstem, such as cranial nerve nuclei, the supraoculomotor area, the medial longitudinal fasciculus, and paramedian pontine formation [<xref rid="B142-jcm-13-05114" ref-type="bibr">142</xref>], was not possible according to our retrospective MRI analyses. In the literature cohort, 34% of patients developed strabismus. Among these patients, 9% had a hypomyelinating form of leukodystrophy, and 91% had a demyelinating form of leukodystrophy.</p>
      <p>Visual function deficits in patients with leukodystrophies have also been reported but are less common, with only 11% in our cohort and 53% in the literature. We assume that the composition of our cohort with a greater percentage of patients in their early disease course might explain this discrepancy as well as the method used for the literature search, as an association between leukodystrophy and visual deficits was explicitly sought.</p>
      <p>Abnormalities in pupillary light reflexes according to clinical examination were less frequent in our cohort (14%) than in the literature cohort (39%). As abnormal myelination usually affects the nerve conduction velocity, we assume that subtle changes in the reaction time of pupillary light reflexes might be persistent but would need more sensitive methods, such as pupillometry. This topic is subject to further research. </p>
      <p>Pathologic findings of the anterior and periocular segments occurred in 11% of our cohort. Inflammation, such as blepharitis, conjunctivitis, or hordoleum, was most common in patients with Canavan disease (42%, <italic toggle="yes">n</italic> = 3/7). Prospective studies are necessary to reveal potential causes, such as reduced blinking frequencies, in children with CD. As previously published, cataracts were present in patients with CTX [<xref rid="B20-jcm-13-05114" ref-type="bibr">20</xref>].</p>
      <p>Analysis of 54 patients with VEP revealed a pathologic finding in the majority of the reported examinations (65%), which is in line with the results in the LCC where 66% also showed pathological VEP findings (52 of 79 patients). When grouped by hypomyelinating and demyelinating forms of leukodystrophies, pathological VEP findings were noted in 100% (<italic toggle="yes">n</italic> = 8/8) of our cohort in the group with hypomyelinating leukodystrophies (83% in LCC) and in 59% (<italic toggle="yes">n</italic> = 27/46) of our cohort in the group with demyelinating forms of leukodystrophies (61% in LCC).</p>
      <p>Involvement of the optic nerve during disease progression is a known feature of leukodystrophies. As an example in MLD, histopathological findings have revealed metachromatic deposits in retinal ganglion cells, optic nerves, and ciliary nerves [<xref rid="B143-jcm-13-05114" ref-type="bibr">143</xref>]. Optic atrophy is mainly described later during the disease course [<xref rid="B2-jcm-13-05114" ref-type="bibr">2</xref>]. We believe the normal VEP results in 19 patients can be attributed to the early timing of the examinations, conducted at a median of 15 months after disease onset.</p>
      <p>The discrepancies in the frequency of ophthalmologic findings between HLC and LLC data might be explained by the selection of studies or articles based on predefined search criteria and keywords. There might be an overestimation of the incidence in the literature as reported cases are often more severely affected or have a longer follow-up time. In our cohort, there are many cases who are still early in the course of the disease, for whom we suspect that neuro-ophthalmologic symptoms may still occur during the course of the disease. A follow-up would be useful and would provide information about the actual differences in frequency. A prospective systematic evaluation based on research would allow a significant reduction in this bias.</p>
      <p>In our study, the OCT data of 9 patients with leukodystrophy were analyzed. Six patients with MLD (<italic toggle="yes">n</italic> = 2), X-ALD (<italic toggle="yes">n</italic> = 2), CTX (<italic toggle="yes">n</italic> = 1), or MLC (<italic toggle="yes">n</italic> = 1) and normal OCT findings were not in an advanced stage of the disease or suffered from a slowly progressive form of leukodystrophy. Three patients, two with KD and one with 4H syndrome, showed abnormal thinning of the retinal nerve fiber layer (RNFL). All patients with pathologic OCT presented at a progressed stage of disease and presented optic atrophy when OCT was performed. Interestingly, no reports of abnormal RNFL thinning in Krabbe disease or 4H syndrome patients, including one adult Krabbe patient without abnormal OCT findings [<xref rid="B144-jcm-13-05114" ref-type="bibr">144</xref>], have been published to date. As the thickness of the RNFL is thought to reflect the integrity of the unmyelinated axons of the anterior visual pathway and the CNS white matter, future studies need to analyze the impact of OCT as a surrogate marker for disease progression. We did not observe hyperreflective retinal spots in the three pathologic OCT results of Krabbe and 4H syndrome patients, which are thought to be related to microglia activation [<xref rid="B145-jcm-13-05114" ref-type="bibr">145</xref>]. Due to the limited number of patients who underwent OCT, we assumed that retinal changes might correlate with the degree of progression reflecting later stages of the disease. Further research should evaluate retinal involvement in leukodystrophies using OCT. This may impact decisions in the development of new treatments as not all application routes for CNS treatments might have effects on the retina.</p>
      <p>MRI provides information on the extent and cause of white matter involvement in the brain [<xref rid="B15-jcm-13-05114" ref-type="bibr">15</xref>,<xref rid="B16-jcm-13-05114" ref-type="bibr">16</xref>,<xref rid="B17-jcm-13-05114" ref-type="bibr">17</xref>]. In general, white matter involvement in LDs is bilateral and symmetric [<xref rid="B146-jcm-13-05114" ref-type="bibr">146</xref>]. Characteristic MRI patterns are known for some LDs, which may contribute to the correct diagnosis [<xref rid="B15-jcm-13-05114" ref-type="bibr">15</xref>]. For example, MLD patients show a distinct pattern of demyelination, which is also called the &#x201C;stripe sign&#x201D; or the &#x201C;leopard skin sign&#x201D; with stripes and patches [<xref rid="B147-jcm-13-05114" ref-type="bibr">147</xref>]. There is also a common MRI pattern in X-ALD patients with symmetrical involvement of the parieto-occipital or frontal white matter and the adjacent part of the corpus callosum [<xref rid="B146-jcm-13-05114" ref-type="bibr">146</xref>]. </p>
      <p>As we analyzed cerebral MRI within +/&#x2212; 1.5 years before or after the reported onset of neuro-ophthalmologic symptoms, most MRIs revealed abnormal findings of the visual tract in the HLC. Most commonly, bilateral demyelination of the occipital white matter was found, whereas abnormalities of the optic nerves were second most common.</p>
      <p>Eight patients showed optic nerve kinking on MRI, which, to our knowledge, has not been previously described in leukodystrophies. These patients suffer from CD, KD, PMD, X-ALD, 4H syndrome, and Col4a1. In the literature, optic nerve kinking has for example been reported in optic nerve gliomas, neurofibromatosis 1 [<xref rid="B148-jcm-13-05114" ref-type="bibr">148</xref>,<xref rid="B149-jcm-13-05114" ref-type="bibr">149</xref>], and aneurysms [<xref rid="B150-jcm-13-05114" ref-type="bibr">150</xref>]. Seiff et al. cited the high water content in myxomatous tissue as a possible explanation for kink formation [<xref rid="B151-jcm-13-05114" ref-type="bibr">151</xref>]. The pathophysiology of optic nerve kinking in LDs has yet be solved and may be the focus of future MRI studies. The small number of patients with an MRI analysis may affect the generalizability of the results. The selection criteria were independent of leukodystrophy, gender, age of onset, and disease severity. We therefore assume that this group represents our cohort well.</p>
      <p>However, this study has limitations given the relatively small sample size of the individual leukodystrophies. In addition, data collection was only retrospective, and the length and intervals of the follow-up periods varies considerably. Reports of neuro-ophthalmologic and other clinical symptoms were part of the clinical examinations and not performed on a systematic prospective basis. Currently, for most leukodystrophies, there is no curative treatment available. As palliative care is the main treatment for most patients, complete and regular assessments with MRI, VEP, OCT and ophthalmologic examinations are not done as part of routine clinical care given the health system costs and patient burden. Systematic prospective studies within a research setting would allow a deeper understanding of NOS in leukodystrophies and may allow more targeted development of treatments.</p>
      <p>Further follow-up studies should investigate the occurrence of neuro-ophthalmologic symptoms and the possible improvement of existing symptoms over a longer period of time with or without therapy. This is of interest as the evaluation of individual therapies is still discussed and the development of new treatment approaches is ongoing.</p>
      <p>It must be taken into account that the disease stage of LD is important for the pathology of the optical tract, particularly in the case of demyelinating LD. The results therefore represent a longitudinal section of the course of the disease after diagnosis and should not be used as absolute frequencies of occurrence in the corresponding diseases. The collection of these data in the respective final stage of the diseases would therefore be expected to be associated with considerably higher figures.</p>
    </sec>
    <sec sec-type="conclusions" id="sec5-jcm-13-05114">
      <title>5. Conclusions</title>
      <p>Leukodystrophies remain one of the most devastating inherited neurological disorders in children and young adults. Our results demonstrate the importance of ophthalmic assessments as neuro-ophthalmologic symptoms are common in leukodystrophies and contribute to the burden of disease. An MRI scan of the brain is an appropriate tool to reveal pathologic alterations in the visual tract that are temporally correlated with symptoms. The first OCT findings in Krabbe and 4H syndrome patients demonstrate retinal findings. Further research needs to evaluate occurrence of retinal involvement in leukodystrophies.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>We want to thank all patients and their families who support our leukodystrophy studies. We thank Alfried Kohlsch&#xFC;tter who established the leukodystrophy clinic at Kinder-UKE.</p>
    </ack>
    <fn-group>
      <fn>
        <p><bold>Disclaimer/Publisher&#x2019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p>
      </fn>
    </fn-group>
    <app-group>
      <app id="app1-jcm-13-05114">
        <title>Supplementary Materials</title>
        <p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/jcm13175114/s1">https://www.mdpi.com/article/10.3390/jcm13175114/s1</uri>, Table S1: Optic atrophy in the literature cohort.</p>
        <supplementary-material id="jcm-13-05114-s001" position="float" content-type="local-data">
          <media xlink:href="jcm-13-05114-s001.zip"/>
        </supplementary-material>
      </app>
    </app-group>
    <notes>
      <title>Author Contributions</title>
      <p>A.E.B., J.D. and C.M.B. designed the study. C.M.B. performed data extraction and chart analysis. G.S. performed statistical analyses. C.M.B., A.E.B., S.L.M. and P.G. wrote the manuscript. C.M.B., A.E.B. and H.G. evaluated MRI findings. S.D. and Y.A. performed ophthalmological assessments in some patients and reviewed ophthalmological examination in charts. All authors have read and agreed to the published version of the manuscript.</p>
    </notes>
    <notes>
      <title>Institutional Review Board Statement</title>
      <p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Medical Association of Hamburg, Germany for studies involving humans (PV3782, approved on 7 November 2011 and 4 September 2020). Informed consent was obtained from all living subjects involved in the study.</p>
    </notes>
    <notes>
      <title>Informed Consent Statement</title>
      <p>Informed consent was obtained from all subjects involved in the study. Patient consent was waived if patients were deceased.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data Availability Statement</title>
      <p>The data presented in this study are not available in a more detailed form due to data protection reasons.</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflicts of interest.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="B1-jcm-13-05114">
        <label>1.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
<name><surname>Raymond</surname><given-names>G.V.</given-names></name>
</person-group>
          <article-title>Leukodystrophy: Basic and Clinical</article-title>
          <source>Neurodegenerative Diseases: Pathology, Mechanisms, and Potential Therapeutic Targets</source>
          <person-group person-group-type="editor">
<name><surname>Beart</surname><given-names>P.</given-names></name>
<name><surname>Robinson</surname><given-names>M.</given-names></name>
<name><surname>Rattray</surname><given-names>M.</given-names></name>
<name><surname>Maragakis</surname><given-names>N.J.</given-names></name>
</person-group>
          <publisher-name>Springer International Publishing</publisher-name>
          <publisher-loc>Cham, Switzerland</publisher-loc>
          <year>2017</year>
          <fpage>365</fpage>
          <lpage>382</lpage>
          <pub-id pub-id-type="doi">10.1007/978-3-319-57193-5_14</pub-id>
        </element-citation>
      </ref>
      <ref id="B2-jcm-13-05114">
        <label>2.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van der Knaap</surname><given-names>M.S.</given-names></name>
<name><surname>Bugiani</surname><given-names>M.</given-names></name>
</person-group><article-title>Leukodystrophies: A proposed classification system based on pathological changes and pathogenetic mechanisms</article-title><source>Acta Neuropathol.</source><year>2017</year><volume>134</volume><fpage>351</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1007/s00401-017-1739-1</pub-id><pub-id pub-id-type="pmid">28638987</pub-id>
</element-citation>
      </ref>
      <ref id="B3-jcm-13-05114">
        <label>3.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kevelam</surname><given-names>S.H.</given-names></name>
<name><surname>Steenweg</surname><given-names>M.E.</given-names></name>
<name><surname>Srivastava</surname><given-names>S.</given-names></name>
<name><surname>Helman</surname><given-names>G.</given-names></name>
<name><surname>Naidu</surname><given-names>S.</given-names></name>
<name><surname>Schiffmann</surname><given-names>R.</given-names></name>
<name><surname>Blaser</surname><given-names>S.</given-names></name>
<name><surname>Vanderver</surname><given-names>A.</given-names></name>
<name><surname>Wolf</surname><given-names>N.I.</given-names></name>
<name><surname>van der Knaap</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Update on Leukodystrophies: A Historical Perspective and Adapted Definition</article-title><source>Neuropediatrics</source><year>2016</year><volume>47</volume><fpage>349</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1055/s-0036-1588020</pub-id><pub-id pub-id-type="pmid">27564080</pub-id>
</element-citation>
      </ref>
      <ref id="B4-jcm-13-05114">
        <label>4.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bugiani</surname><given-names>M.</given-names></name>
<name><surname>van der Knaap</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Childhood white matter disorders: Much more than just diseases of myelin</article-title><source>Acta Neuropathologica</source><year>2017</year><volume>134</volume><fpage>329</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1007/s00401-017-1750-6</pub-id><pub-id pub-id-type="pmid">28725966</pub-id>
</element-citation>
      </ref>
      <ref id="B5-jcm-13-05114">
        <label>5.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vanderver</surname><given-names>A.</given-names></name>
<name><surname>Prust</surname><given-names>M.</given-names></name>
<name><surname>Tonduti</surname><given-names>D.</given-names></name>
<name><surname>Mochel</surname><given-names>F.</given-names></name>
<name><surname>Hussey</surname><given-names>H.M.</given-names></name>
<name><surname>Helman</surname><given-names>G.</given-names></name>
<name><surname>Garbern</surname><given-names>J.</given-names></name>
<name><surname>Eichler</surname><given-names>F.</given-names></name>
<name><surname>Labauge</surname><given-names>P.</given-names></name>
<name><surname>Aubourg</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Case definition and classification of leukodystrophies and leukoencephalopathies</article-title><source>Mol. Genet. Metab.</source><year>2015</year><volume>114</volume><fpage>494</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2015.01.006</pub-id><pub-id pub-id-type="pmid">25649058</pub-id>
</element-citation>
      </ref>
      <ref id="B6-jcm-13-05114">
        <label>6.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kohlsch&#xFC;tter</surname><given-names>A.</given-names></name>
<name><surname>Eichler</surname><given-names>F.</given-names></name>
</person-group><article-title>Childhood leukodystrophies: A clinical perspective</article-title><source>Expert. Rev. Neurother.</source><year>2011</year><volume>11</volume><fpage>1485</fpage><lpage>1496</lpage><pub-id pub-id-type="doi">10.1586/ern.11.135</pub-id><pub-id pub-id-type="pmid">21955203</pub-id>
</element-citation>
      </ref>
      <ref id="B7-jcm-13-05114">
        <label>7.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Costello</surname><given-names>D.J.</given-names></name>
<name><surname>Eichler</surname><given-names>A.F.</given-names></name>
<name><surname>Eichler</surname><given-names>F.S.</given-names></name>
</person-group><article-title>Leukodystrophies: Classification, diagnosis, and treatment</article-title><source>Neurologist</source><year>2009</year><volume>15</volume><fpage>319</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1097/NRL.0b013e3181b287c8</pub-id><pub-id pub-id-type="pmid">19901710</pub-id>
</element-citation>
      </ref>
      <ref id="B8-jcm-13-05114">
        <label>8.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torii</surname><given-names>T.</given-names></name>
<name><surname>Yamauchi</surname><given-names>J.</given-names></name>
</person-group><article-title>Molecular Pathogenic Mechanisms of Hypomyelinating Leukodystrophies (HLDs)</article-title><source>Neurol. Int.</source><year>2023</year><volume>15</volume><fpage>1155</fpage><lpage>1173</lpage><pub-id pub-id-type="doi">10.3390/neurolint15030072</pub-id><pub-id pub-id-type="pmid">37755363</pub-id>
</element-citation>
      </ref>
      <ref id="B9-jcm-13-05114">
        <label>9.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wolf</surname><given-names>N.I.</given-names></name>
<name><surname>Ffrench-Constant</surname><given-names>C.</given-names></name>
<name><surname>van der Knaap</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Hypomyelinating leukodystrophies&#x2014;Unravelling myelin biology</article-title><source>Nat. Rev. Neurol.</source><year>2021</year><volume>17</volume><fpage>88</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/s41582-020-00432-1</pub-id><pub-id pub-id-type="pmid">33324001</pub-id>
</element-citation>
      </ref>
      <ref id="B10-jcm-13-05114">
        <label>10.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>K&#xF6;hler</surname><given-names>W.</given-names></name>
<name><surname>Curiel</surname><given-names>J.</given-names></name>
<name><surname>Vanderver</surname><given-names>A.</given-names></name>
</person-group><article-title>Adulthood leukodystrophies</article-title><source>Nat. Rev. Neurol.</source><year>2018</year><volume>14</volume><fpage>94</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2017.175</pub-id><pub-id pub-id-type="pmid">29302065</pub-id>
</element-citation>
      </ref>
      <ref id="B11-jcm-13-05114">
        <label>11.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Rappard</surname><given-names>D.F.</given-names></name>
<name><surname>Boelens</surname><given-names>J.J.</given-names></name>
<name><surname>Wolf</surname><given-names>N.I.</given-names></name>
</person-group><article-title>Metachromatic leukodystrophy: Disease spectrum and approaches for treatment</article-title><source>Best. Pract. Res. Clin. Endocrinol. Metab.</source><year>2015</year><volume>29</volume><fpage>261</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1016/j.beem.2014.10.001</pub-id><pub-id pub-id-type="pmid">25987178</pub-id>
</element-citation>
      </ref>
      <ref id="B12-jcm-13-05114">
        <label>12.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patil</surname><given-names>S.A.</given-names></name>
<name><surname>Maegawa</surname><given-names>G.H.</given-names></name>
</person-group><article-title>Developing therapeutic approaches for metachromatic leukodystrophy</article-title><source>Drug Des. Devel. Ther.</source><year>2013</year><volume>7</volume><fpage>729</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.2147/dddt.S15467</pub-id><pub-id pub-id-type="pmid">23966770</pub-id>
</element-citation>
      </ref>
      <ref id="B13-jcm-13-05114">
        <label>13.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parikh</surname><given-names>S.</given-names></name>
<name><surname>Bernard</surname><given-names>G.</given-names></name>
<name><surname>Leventer</surname><given-names>R.J.</given-names></name>
<name><surname>van der Knaap</surname><given-names>M.S.</given-names></name>
<name><surname>van Hove</surname><given-names>J.</given-names></name>
<name><surname>Pizzino</surname><given-names>A.</given-names></name>
<name><surname>McNeill</surname><given-names>N.H.</given-names></name>
<name><surname>Helman</surname><given-names>G.</given-names></name>
<name><surname>Simons</surname><given-names>C.</given-names></name>
<name><surname>Schmidt</surname><given-names>J.L.</given-names></name>
<etal/>
</person-group><article-title>A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies</article-title><source>Mol. Genet. Metab.</source><year>2015</year><volume>114</volume><fpage>501</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2014.12.434</pub-id><pub-id pub-id-type="pmid">25655951</pub-id>
</element-citation>
      </ref>
      <ref id="B14-jcm-13-05114">
        <label>14.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ashrafi</surname><given-names>M.R.</given-names></name>
<name><surname>Tavasoli</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Childhood leukodystrophies: A literature review of updates on new definitions, classification, diagnostic approach and management</article-title><source>Brain Dev.</source><year>2017</year><volume>39</volume><fpage>369</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2017.01.001</pub-id><pub-id pub-id-type="pmid">28117190</pub-id>
</element-citation>
      </ref>
      <ref id="B15-jcm-13-05114">
        <label>15.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ashrafi</surname><given-names>M.R.</given-names></name>
<name><surname>Amanat</surname><given-names>M.</given-names></name>
<name><surname>Garshasbi</surname><given-names>M.</given-names></name>
<name><surname>Kameli</surname><given-names>R.</given-names></name>
<name><surname>Nilipour</surname><given-names>Y.</given-names></name>
<name><surname>Heidari</surname><given-names>M.</given-names></name>
<name><surname>Rezaei</surname><given-names>Z.</given-names></name>
<name><surname>Tavasoli</surname><given-names>A.R.</given-names></name>
</person-group><article-title>An update on clinical, pathological, diagnostic, and therapeutic perspectives of childhood leukodystrophies</article-title><source>Expert. Rev. Neurother.</source><year>2020</year><volume>20</volume><fpage>65</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1080/14737175.2020.1699060</pub-id><pub-id pub-id-type="pmid">31829048</pub-id>
</element-citation>
      </ref>
      <ref id="B16-jcm-13-05114">
        <label>16.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davidsdottir</surname><given-names>S.</given-names></name>
<name><surname>Cronin-Golomb</surname><given-names>A.</given-names></name>
<name><surname>Lee</surname><given-names>A.</given-names></name>
</person-group><article-title>Visual and spatial symptoms in Parkinson&#x2019;s disease</article-title><source>Vision. Res.</source><year>2005</year><volume>45</volume><fpage>1285</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1016/j.visres.2004.11.006</pub-id><pub-id pub-id-type="pmid">15733961</pub-id>
</element-citation>
      </ref>
      <ref id="B17-jcm-13-05114">
        <label>17.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jasse</surname><given-names>L.</given-names></name>
<name><surname>Vukusic</surname><given-names>S.</given-names></name>
<name><surname>Durand-Dubief</surname><given-names>F.</given-names></name>
<name><surname>Vartin</surname><given-names>C.</given-names></name>
<name><surname>Piras</surname><given-names>C.</given-names></name>
<name><surname>Bernard</surname><given-names>M.</given-names></name>
<name><surname>P&#xE9;lisson</surname><given-names>D.</given-names></name>
<name><surname>Confavreux</surname><given-names>C.</given-names></name>
<name><surname>Vighetto</surname><given-names>A.</given-names></name>
<name><surname>Tilikete</surname><given-names>C.</given-names></name>
</person-group><article-title>Persistent visual impairment in multiple sclerosis: Prevalence, mechanisms and resulting disability</article-title><source>Mult. Scler.</source><year>2013</year><volume>19</volume><fpage>1618</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.1177/1352458513479840</pub-id><pub-id pub-id-type="pmid">23462348</pub-id>
</element-citation>
      </ref>
      <ref id="B18-jcm-13-05114">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Urwyler</surname><given-names>P.</given-names></name>
<name><surname>Nef</surname><given-names>T.</given-names></name>
<name><surname>Killen</surname><given-names>A.</given-names></name>
<name><surname>Collerton</surname><given-names>D.</given-names></name>
<name><surname>Thomas</surname><given-names>A.</given-names></name>
<name><surname>Burn</surname><given-names>D.</given-names></name>
<name><surname>McKeith</surname><given-names>I.</given-names></name>
<name><surname>Mosimann</surname><given-names>U.P.</given-names></name>
</person-group>
          <article-title>Visual complaints and visual hallucinations in Parkinson&#x2019;s disease</article-title>
          <source>Park. Relat. Disord.</source>
          <year>2014</year>
          <volume>20</volume>
          <fpage>318</fpage>
          <lpage>322</lpage>
          <pub-id pub-id-type="doi">10.1016/j.parkreldis.2013.12.009</pub-id>
        </element-citation>
      </ref>
      <ref id="B19-jcm-13-05114">
        <label>19.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
<name><surname>Bowen</surname><given-names>M.</given-names></name>
<name><surname>Edgar</surname><given-names>D.F.</given-names></name>
<name><surname>Hancock</surname><given-names>B.</given-names></name>
<name><surname>Haque</surname><given-names>S.</given-names></name>
<name><surname>Shah</surname><given-names>R.</given-names></name>
<name><surname>Buchanan</surname><given-names>S.</given-names></name>
<name><surname>Iliffe</surname><given-names>S.</given-names></name>
<name><surname>Maskell</surname><given-names>S.</given-names></name>
<name><surname>Pickett</surname><given-names>J.</given-names></name>
<name><surname>Taylor</surname><given-names>J.P.</given-names></name>
<etal/>
</person-group>
          <article-title>Health Services and Delivery Research</article-title>
          <source>The Prevalence of Visual Impairment in People with Dementia (the PrOVIDe Study): A Cross-Sectional Study of People Aged 60&#x2013;89 Years with Dementia and Qualitative Exploration of Individual, Carer and Professional Perspectives</source>
          <publisher-name>NIHR Journals Library</publisher-name>
          <publisher-loc>Southampton, UK</publisher-loc>
          <year>2016</year>
        </element-citation>
      </ref>
      <ref id="B20-jcm-13-05114">
        <label>20.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kohlsch&#xFC;tter</surname><given-names>A.</given-names></name>
<name><surname>Bley</surname><given-names>A.</given-names></name>
<name><surname>Brockmann</surname><given-names>K.</given-names></name>
<name><surname>G&#xE4;rtner</surname><given-names>J.</given-names></name>
<name><surname>Kr&#xE4;geloh-Mann</surname><given-names>I.</given-names></name>
<name><surname>Rolfs</surname><given-names>A.</given-names></name>
<name><surname>Sch&#xF6;ls</surname><given-names>L.</given-names></name>
</person-group><article-title>Leukodystrophies and other genetic metabolic leukoencephalopathies in children and adults</article-title><source>Brain Dev.</source><year>2010</year><volume>32</volume><fpage>82</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2009.03.014</pub-id><pub-id pub-id-type="pmid">19427149</pub-id>
</element-citation>
      </ref>
      <ref id="B21-jcm-13-05114">
        <label>21.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vaphiades</surname><given-names>M.S.</given-names></name>
<name><surname>Brodsky</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Pediatric optic atrophy</article-title><source>Int. Ophthalmol. Clin.</source><year>2012</year><volume>52</volume><fpage>17</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1097/IIO.0b013e31825a14ba</pub-id><pub-id pub-id-type="pmid">22668537</pub-id>
</element-citation>
      </ref>
      <ref id="B22-jcm-13-05114">
        <label>22.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
<name><surname>Mehra</surname><given-names>D.</given-names></name>
<name><surname>Moshirfar</surname><given-names>M.</given-names></name>
</person-group>
          <article-title>Neuroanatomy, Optic Tract</article-title>
          <source>StatPearls</source>
          <publisher-name>StatPearls Publishing</publisher-name>
          <publisher-loc>Treasure Island, FL, USA</publisher-loc>
          <year>2021</year>
        </element-citation>
      </ref>
      <ref id="B23-jcm-13-05114">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Odom</surname><given-names>J.V.</given-names></name>
<name><surname>Bach</surname><given-names>M.</given-names></name>
<name><surname>Brigell</surname><given-names>M.</given-names></name>
<name><surname>Holder</surname><given-names>G.E.</given-names></name>
<name><surname>McCulloch</surname><given-names>D.L.</given-names></name>
<name><surname>Mizota</surname><given-names>A.</given-names></name>
<name><surname>Tormene</surname><given-names>A.P.</given-names></name>
<collab>International Society for Clinical Electrophysiology of Vision</collab>
</person-group>
          <article-title>ISCEV standard for clinical visual evoked potentials: (2016 update)</article-title>
          <source>Doc. Ophthalmol.</source>
          <year>2016</year>
          <volume>133</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1007/s10633-016-9553-y</pub-id>
        </element-citation>
      </ref>
      <ref id="B24-jcm-13-05114">
        <label>24.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ji</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>D.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Gu</surname><given-names>Q.</given-names></name>
<name><surname>Xie</surname><given-names>H.</given-names></name>
<name><surname>Ji</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Hypomyelinating disorders in China: The clinical and genetic heterogeneity in 119 patients</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0188869</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0188869</pub-id><pub-id pub-id-type="pmid">29451896</pub-id>
</element-citation>
      </ref>
      <ref id="B25-jcm-13-05114">
        <label>25.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Srivastava</surname><given-names>S.</given-names></name>
<name><surname>Butala</surname><given-names>A.</given-names></name>
<name><surname>Mahida</surname><given-names>S.</given-names></name>
<name><surname>Richter</surname><given-names>J.</given-names></name>
<name><surname>Mu</surname><given-names>W.</given-names></name>
<name><surname>Poretti</surname><given-names>A.</given-names></name>
<name><surname>Vernon</surname><given-names>H.</given-names></name>
<name><surname>VanGerpen</surname><given-names>J.</given-names></name>
<name><surname>Atwal</surname><given-names>P.S.</given-names></name>
<name><surname>Middlebrooks</surname><given-names>E.H.</given-names></name>
<etal/>
</person-group><article-title>Expansion of the clinical spectrum associated with AARS2-related disorders</article-title><source>Am. J. Med. Genet. A</source><year>2019</year><volume>179</volume><fpage>1556</fpage><lpage>1564</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.61188</pub-id><pub-id pub-id-type="pmid">31099476</pub-id>
</element-citation>
      </ref>
      <ref id="B26-jcm-13-05114">
        <label>26.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goebel</surname><given-names>H.H.</given-names></name>
<name><surname>Busch-Hettwer</surname><given-names>H.</given-names></name>
<name><surname>Bohl</surname><given-names>J.</given-names></name>
</person-group><article-title>Ultrastructural study of the retina in late infantile metachromatic leukodystrophy</article-title><source>Ophthalmic Res.</source><year>1992</year><volume>24</volume><fpage>103</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1159/000267154</pub-id><pub-id pub-id-type="pmid">1608595</pub-id>
</element-citation>
      </ref>
      <ref id="B27-jcm-13-05114">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Johal</surname><given-names>J.</given-names></name>
<name><surname>Castro Apolo</surname><given-names>R.</given-names></name>
<name><surname>Johnson</surname><given-names>M.W.</given-names></name>
<name><surname>Persch</surname><given-names>M.R.</given-names></name>
<name><surname>Edwards</surname><given-names>A.</given-names></name>
<name><surname>Varade</surname><given-names>P.</given-names></name>
<name><surname>Yacoub</surname><given-names>H.</given-names></name>
</person-group>
          <article-title>Adult polyglucosan body disease: An acute presentation leading to unmasking of this rare disorder</article-title>
          <source>Hosp. Pract.</source>
          <year>2022</year>
          <volume>50</volume>
          <fpage>244</fpage>
          <lpage>250</lpage>
          <pub-id pub-id-type="doi">10.1080/21548331.2021.1874182</pub-id>
        </element-citation>
      </ref>
      <ref id="B28-jcm-13-05114">
        <label>28.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishihara</surname><given-names>K.</given-names></name>
<name><surname>Horibe</surname><given-names>Y.</given-names></name>
<name><surname>Ohno</surname><given-names>H.</given-names></name>
<name><surname>Sugie</surname><given-names>M.</given-names></name>
<name><surname>Shiota</surname><given-names>J.</given-names></name>
<name><surname>Nakano</surname><given-names>I.</given-names></name>
<name><surname>Kawamura</surname><given-names>M.</given-names></name>
</person-group><article-title>A clinicopathological study of young-onset dementia: Report of 2 autopsied cases</article-title><source>Brain Nerve</source><year>2011</year><volume>63</volume><fpage>1117</fpage><lpage>1123</lpage><pub-id pub-id-type="pmid">21987568</pub-id>
</element-citation>
      </ref>
      <ref id="B29-jcm-13-05114">
        <label>29.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giroud</surname><given-names>M.</given-names></name>
<name><surname>Gouyon</surname><given-names>J.B.</given-names></name>
<name><surname>Chaumet</surname><given-names>F.</given-names></name>
<name><surname>Cinquin</surname><given-names>A.M.</given-names></name>
<name><surname>Chevalier-Nivelon</surname><given-names>A.</given-names></name>
<name><surname>Alison</surname><given-names>M.</given-names></name>
<name><surname>Dumas</surname><given-names>R.</given-names></name>
</person-group><article-title>A case of progressive familial encephalopathy in infancy with calcification of the basal ganglia and chronic cerebrospinal fluid lymphocytosis</article-title><source>Childs Nerv. Syst.</source><year>1986</year><volume>2</volume><fpage>47</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1007/BF00274035</pub-id><pub-id pub-id-type="pmid">3731164</pub-id>
</element-citation>
      </ref>
      <ref id="B30-jcm-13-05114">
        <label>30.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Viguera-El&#xED;as</surname><given-names>D.</given-names></name>
<name><surname>de la Iglesia-Nagore</surname><given-names>I.</given-names></name>
<name><surname>Toledo-Gotor</surname><given-names>C.</given-names></name>
<name><surname>Dom&#xED;nguez-Garrido</surname><given-names>E.</given-names></name>
<name><surname>Poch-Oliv&#xE9;</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Aicardi-Goutieres syndrome: A family case due to alteration of the RNASEH2B gene</article-title><source>Rev. Neurol.</source><year>2021</year><volume>72</volume><fpage>407</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.33588/rn.7211.2021071</pub-id><pub-id pub-id-type="pmid">34042169</pub-id>
</element-citation>
      </ref>
      <ref id="B31-jcm-13-05114">
        <label>31.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nishri</surname><given-names>D.</given-names></name>
<name><surname>Edvardson</surname><given-names>S.</given-names></name>
<name><surname>Lev</surname><given-names>D.</given-names></name>
<name><surname>Leshinsky-Silver</surname><given-names>E.</given-names></name>
<name><surname>Ben-Sira</surname><given-names>L.</given-names></name>
<name><surname>Henneke</surname><given-names>M.</given-names></name>
<name><surname>Lerman-Sagie</surname><given-names>T.</given-names></name>
<name><surname>Blumkin</surname><given-names>L.</given-names></name>
</person-group><article-title>Diagnosis by whole exome sequencing of atypical infantile onset Alexander disease masquerading as a mitochondrial disorder</article-title><source>Eur. J. Paediatr. Neurol.</source><year>2014</year><volume>18</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/j.ejpn.2014.03.009</pub-id><pub-id pub-id-type="pmid">24742911</pub-id>
</element-citation>
      </ref>
      <ref id="B32-jcm-13-05114">
        <label>32.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pfeffer</surname><given-names>G.</given-names></name>
<name><surname>Abegg</surname><given-names>M.</given-names></name>
<name><surname>Vertinsky</surname><given-names>A.T.</given-names></name>
<name><surname>Ceccherini</surname><given-names>I.</given-names></name>
<name><surname>Caroli</surname><given-names>F.</given-names></name>
<name><surname>Barton</surname><given-names>J.J.</given-names></name>
</person-group><article-title>The ocular motor features of adult-onset alexander disease: A case and review of the literature</article-title><source>J. Neuroophthalmol.</source><year>2011</year><volume>31</volume><fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1097/WNO.0b013e31820ecb28</pub-id><pub-id pub-id-type="pmid">21403579</pub-id>
</element-citation>
      </ref>
      <ref id="B33-jcm-13-05114">
        <label>33.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Namekawa</surname><given-names>M.</given-names></name>
<name><surname>Takiyama</surname><given-names>Y.</given-names></name>
<name><surname>Honda</surname><given-names>J.</given-names></name>
<name><surname>Shimazaki</surname><given-names>H.</given-names></name>
<name><surname>Sakoe</surname><given-names>K.</given-names></name>
<name><surname>Nakano</surname><given-names>I.</given-names></name>
</person-group><article-title>Adult-onset Alexander disease with typical &#x201C;tadpole&#x201D; brainstem atrophy and unusual bilateral basal ganglia involvement: A case report and review of the literature</article-title><source>BMC Neurol.</source><year>2010</year><volume>10</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2377-10-21</pub-id><pub-id pub-id-type="pmid">20359319</pub-id>
</element-citation>
      </ref>
      <ref id="B34-jcm-13-05114">
        <label>34.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martidis</surname><given-names>A.</given-names></name>
<name><surname>Yee</surname><given-names>R.D.</given-names></name>
<name><surname>Azzarelli</surname><given-names>B.</given-names></name>
<name><surname>Biller</surname><given-names>J.</given-names></name>
</person-group><article-title>Neuro-ophthalmic, radiographic, and pathologic manifestations of adult-onset Alexander disease</article-title><source>Arch. Ophthalmol.</source><year>1999</year><volume>117</volume><fpage>265</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1001/archopht.117.2.265</pub-id><pub-id pub-id-type="pmid">10037578</pub-id>
</element-citation>
      </ref>
      <ref id="B35-jcm-13-05114">
        <label>35.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nikam</surname><given-names>R.M.</given-names></name>
<name><surname>Gripp</surname><given-names>K.W.</given-names></name>
<name><surname>Choudhary</surname><given-names>A.K.</given-names></name>
<name><surname>Kandula</surname><given-names>V.</given-names></name>
</person-group><article-title>Imaging phenotype of multiple mitochondrial dysfunction syndrome 2, a rare BOLA3-associated leukodystrophy</article-title><source>Am. J. Med. Genet. A</source><year>2018</year><volume>176</volume><fpage>2787</fpage><lpage>2790</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.40490</pub-id><pub-id pub-id-type="pmid">30302924</pub-id>
</element-citation>
      </ref>
      <ref id="B36-jcm-13-05114">
        <label>36.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Edvardson</surname><given-names>S.</given-names></name>
<name><surname>Kose</surname><given-names>S.</given-names></name>
<name><surname>Jalas</surname><given-names>C.</given-names></name>
<name><surname>Fattal-Valevski</surname><given-names>A.</given-names></name>
<name><surname>Watanabe</surname><given-names>A.</given-names></name>
<name><surname>Ogawa</surname><given-names>Y.</given-names></name>
<name><surname>Mamada</surname><given-names>H.</given-names></name>
<name><surname>Fedick</surname><given-names>A.M.</given-names></name>
<name><surname>Ben-Shachar</surname><given-names>S.</given-names></name>
<name><surname>Treff</surname><given-names>N.R.</given-names></name>
<etal/>
</person-group><article-title>Leukoencephalopathy and early death associated with an Ashkenazi-Jewish founder mutation in the Hikeshi gene</article-title><source>J. Med. Genet.</source><year>2016</year><volume>53</volume><fpage>132</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2015-103232</pub-id><pub-id pub-id-type="pmid">26545878</pub-id>
</element-citation>
      </ref>
      <ref id="B37-jcm-13-05114">
        <label>37.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pretegiani</surname><given-names>E.</given-names></name>
<name><surname>Rosini</surname><given-names>F.</given-names></name>
<name><surname>Dotti</surname><given-names>M.T.</given-names></name>
<name><surname>Bianchi</surname><given-names>S.</given-names></name>
<name><surname>Federico</surname><given-names>A.</given-names></name>
<name><surname>Rufa</surname><given-names>A.</given-names></name>
</person-group><article-title>Visual system involvement in CADASIL</article-title><source>J. Stroke Cerebrovasc. Dis.</source><year>2013</year><volume>22</volume><fpage>1377</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2013.03.032</pub-id><pub-id pub-id-type="pmid">23635925</pub-id>
</element-citation>
      </ref>
      <ref id="B38-jcm-13-05114">
        <label>38.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gowda</surname><given-names>V.K.</given-names></name>
<name><surname>Bhat</surname><given-names>M.D.</given-names></name>
<name><surname>Srinivasan</surname><given-names>V.M.</given-names></name>
<name><surname>Prasad</surname><given-names>C.</given-names></name>
<name><surname>Benakappa</surname><given-names>A.</given-names></name>
<name><surname>Faruq</surname><given-names>M.</given-names></name>
</person-group><article-title>A case of Canavan disease with microcephaly</article-title><source>Brain Dev.</source><year>2016</year><volume>38</volume><fpage>759</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2016.03.001</pub-id><pub-id pub-id-type="pmid">26992473</pub-id>
</element-citation>
      </ref>
      <ref id="B39-jcm-13-05114">
        <label>39.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drenckhahn</surname><given-names>A.</given-names></name>
<name><surname>Schuelke</surname><given-names>M.</given-names></name>
<name><surname>Knierim</surname><given-names>E.</given-names></name>
</person-group><article-title>Leukodystrophy with multiple beaded periventricular cysts: Unusual cranial MRI results in Canavan disease</article-title><source>J. Inherit. Metab. Dis.</source><year>2015</year><volume>38</volume><fpage>983</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1007/s10545-015-9812-1</pub-id><pub-id pub-id-type="pmid">25647544</pub-id>
</element-citation>
      </ref>
      <ref id="B40-jcm-13-05114">
        <label>40.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gowda</surname><given-names>V.K.</given-names></name>
<name><surname>Bharathi</surname><given-names>N.K.</given-names></name>
<name><surname>Bettaiah</surname><given-names>J.</given-names></name>
<name><surname>Bhat</surname><given-names>M.</given-names></name>
<name><surname>Shivappa</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Canavan Disease: Clinical and Laboratory Profile from Southern Part of India</article-title><source>Ann. Indian. Acad. Neurol.</source><year>2021</year><volume>24</volume><fpage>347</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.4103/aian.AIAN_386_20</pub-id><pub-id pub-id-type="pmid">34446995</pub-id>
</element-citation>
      </ref>
      <ref id="B41-jcm-13-05114">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Karimzadeh</surname><given-names>P.</given-names></name>
<name><surname>Jafari</surname><given-names>N.</given-names></name>
<name><surname>Nejad Biglari</surname><given-names>H.</given-names></name>
<name><surname>Rahimian</surname><given-names>E.</given-names></name>
<name><surname>Ahmadabadi</surname><given-names>F.</given-names></name>
<name><surname>Nemati</surname><given-names>H.</given-names></name>
<name><surname>Nasehi</surname><given-names>M.M.</given-names></name>
<name><surname>Ghofrani</surname><given-names>M.</given-names></name>
<name><surname>Mollamohammadi</surname><given-names>M.</given-names></name>
</person-group>
          <article-title>The Clinical Features and Diagnosis of Canavan&#x2019;s Disease: A Case Series of Iranian Patients</article-title>
          <source>Iran. J. Child. Neurol.</source>
          <year>2014</year>
          <volume>8</volume>
          <fpage>66</fpage>
          <lpage>71</lpage>
        </element-citation>
      </ref>
      <ref id="B42-jcm-13-05114">
        <label>42.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>Z.</given-names></name>
<name><surname>Lu</surname><given-names>T.</given-names></name>
<name><surname>Peng</surname><given-names>L.</given-names></name>
<name><surname>Cheng</surname><given-names>H.</given-names></name>
<name><surname>Peng</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Lu</surname><given-names>Z.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Qiu</surname><given-names>W.</given-names></name>
</person-group><article-title>CLCN2-related leukoencephalopathy: A case report and review of the literature</article-title><source>BMC Neurol.</source><year>2019</year><volume>19</volume><elocation-id>156</elocation-id><pub-id pub-id-type="doi">10.1186/s12883-019-1390-7</pub-id><pub-id pub-id-type="pmid">31291907</pub-id>
</element-citation>
      </ref>
      <ref id="B43-jcm-13-05114">
        <label>43.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riedhammer</surname><given-names>K.M.</given-names></name>
<name><surname>Stockler</surname><given-names>S.</given-names></name>
<name><surname>Ploski</surname><given-names>R.</given-names></name>
<name><surname>Wenzel</surname><given-names>M.</given-names></name>
<name><surname>Adis-Dutschmann</surname><given-names>B.</given-names></name>
<name><surname>Ahting</surname><given-names>U.</given-names></name>
<name><surname>Alhaddad</surname><given-names>B.</given-names></name>
<name><surname>Blaschek</surname><given-names>A.</given-names></name>
<name><surname>Haack</surname><given-names>T.B.</given-names></name>
<name><surname>Kopajtich</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>De novo stop-loss variants in CLDN11 cause hypomyelinating leukodystrophy</article-title><source>Brain</source><year>2021</year><volume>144</volume><fpage>411</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1093/brain/awaa410</pub-id><pub-id pub-id-type="pmid">33313762</pub-id>
</element-citation>
      </ref>
      <ref id="B44-jcm-13-05114">
        <label>44.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Orcesi</surname><given-names>S.</given-names></name>
<name><surname>La Piana</surname><given-names>R.</given-names></name>
<name><surname>Uggetti</surname><given-names>C.</given-names></name>
<name><surname>Tonduti</surname><given-names>D.</given-names></name>
<name><surname>Pichiecchio</surname><given-names>A.</given-names></name>
<name><surname>Pasin</surname><given-names>M.</given-names></name>
<name><surname>Viselner</surname><given-names>G.</given-names></name>
<name><surname>Comi</surname><given-names>G.P.</given-names></name>
<name><surname>Del Bo</surname><given-names>R.</given-names></name>
<name><surname>Ronchi</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Spinal cord calcification in an early-onset progressive leukoencephalopathy</article-title><source>J. Child. Neurol.</source><year>2011</year><volume>26</volume><fpage>876</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1177/0883073810390038</pub-id><pub-id pub-id-type="pmid">21427441</pub-id>
</element-citation>
      </ref>
      <ref id="B45-jcm-13-05114">
        <label>45.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pant</surname><given-names>D.C.</given-names></name>
<name><surname>Dorboz</surname><given-names>I.</given-names></name>
<name><surname>Schluter</surname><given-names>A.</given-names></name>
<name><surname>Fourcade</surname><given-names>S.</given-names></name>
<name><surname>Launay</surname><given-names>N.</given-names></name>
<name><surname>Joya</surname><given-names>J.</given-names></name>
<name><surname>Aguilera-Albesa</surname><given-names>S.</given-names></name>
<name><surname>Yoldi</surname><given-names>M.E.</given-names></name>
<name><surname>Casasnovas</surname><given-names>C.</given-names></name>
<name><surname>Willis</surname><given-names>M.J.</given-names></name>
<etal/>
</person-group><article-title>Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy</article-title><source>J. Clin. Invest.</source><year>2019</year><volume>129</volume><fpage>1240</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.1172/JCI123959</pub-id><pub-id pub-id-type="pmid">30620337</pub-id>
</element-citation>
      </ref>
      <ref id="B46-jcm-13-05114">
        <label>46.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fiumara</surname><given-names>A.</given-names></name>
<name><surname>Barone</surname><given-names>R.</given-names></name>
<name><surname>Arena</surname><given-names>A.</given-names></name>
<name><surname>Filocamo</surname><given-names>M.</given-names></name>
<name><surname>Lissens</surname><given-names>W.</given-names></name>
<name><surname>Pavone</surname><given-names>L.</given-names></name>
<name><surname>Sorge</surname><given-names>G.</given-names></name>
</person-group><article-title>Krabbe leukodystrophy in a selected population with high rate of late onset forms: Longer survival linked to c.121G&gt;A (p.Gly41Ser) mutation</article-title><source>Clin. Genet.</source><year>2011</year><volume>80</volume><fpage>452</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0004.2010.01572.x</pub-id><pub-id pub-id-type="pmid">21070211</pub-id>
</element-citation>
      </ref>
      <ref id="B47-jcm-13-05114">
        <label>47.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harbord</surname><given-names>M.G.</given-names></name>
<name><surname>Finn</surname><given-names>J.P.</given-names></name>
<name><surname>Hall-Craggs</surname><given-names>M.A.</given-names></name>
<name><surname>Brett</surname><given-names>E.M.</given-names></name>
<name><surname>Baraitser</surname><given-names>M.</given-names></name>
</person-group><article-title>Early onset leukodystrophy with distinct facial features in 2 siblings</article-title><source>Neuropediatrics</source><year>1989</year><volume>20</volume><fpage>154</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1055/s-2008-1071282</pub-id><pub-id pub-id-type="pmid">2779744</pub-id>
</element-citation>
      </ref>
      <ref id="B48-jcm-13-05114">
        <label>48.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calame</surname><given-names>D.G.</given-names></name>
<name><surname>Hainlen</surname><given-names>M.</given-names></name>
<name><surname>Takacs</surname><given-names>D.</given-names></name>
<name><surname>Ferrante</surname><given-names>L.</given-names></name>
<name><surname>Pence</surname><given-names>K.</given-names></name>
<name><surname>Emrick</surname><given-names>L.T.</given-names></name>
<name><surname>Chao</surname><given-names>H.T.</given-names></name>
</person-group><article-title>EIF2AK2-related Neurodevelopmental Disorder With Leukoencephalopathy, Developmental Delay, and Episodic Neurologic Regression Mimics Pelizaeus-Merzbacher Disease</article-title><source>Neurol. Genet.</source><year>2021</year><volume>7</volume><fpage>e539</fpage><pub-id pub-id-type="doi">10.1212/NXG.0000000000000539</pub-id><pub-id pub-id-type="pmid">33553620</pub-id>
</element-citation>
      </ref>
      <ref id="B49-jcm-13-05114">
        <label>49.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uhlenberg</surname><given-names>B.</given-names></name>
<name><surname>Schuelke</surname><given-names>M.</given-names></name>
<name><surname>R&#xFC;schendorf</surname><given-names>F.</given-names></name>
<name><surname>Ruf</surname><given-names>N.</given-names></name>
<name><surname>Kaindl</surname><given-names>A.M.</given-names></name>
<name><surname>Henneke</surname><given-names>M.</given-names></name>
<name><surname>Thiele</surname><given-names>H.</given-names></name>
<name><surname>Stoltenburg-Didinger</surname><given-names>G.</given-names></name>
<name><surname>Aksu</surname><given-names>F.</given-names></name>
<name><surname>Topalo&#x11F;lu</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease</article-title><source>Am. J. Hum. Genet.</source><year>2004</year><volume>75</volume><fpage>251</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1086/422763</pub-id><pub-id pub-id-type="pmid">15192806</pub-id>
</element-citation>
      </ref>
      <ref id="B50-jcm-13-05114">
        <label>50.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bugiani</surname><given-names>M.</given-names></name>
<name><surname>Al Shahwan</surname><given-names>S.</given-names></name>
<name><surname>Lamantea</surname><given-names>E.</given-names></name>
<name><surname>Bizzi</surname><given-names>A.</given-names></name>
<name><surname>Bakhsh</surname><given-names>E.</given-names></name>
<name><surname>Moroni</surname><given-names>I.</given-names></name>
<name><surname>Balestrini</surname><given-names>M.R.</given-names></name>
<name><surname>Uziel</surname><given-names>G.</given-names></name>
<name><surname>Zeviani</surname><given-names>M.</given-names></name>
</person-group><article-title>GJA12 mutations in children with recessive hypomyelinating leukoencephalopathy</article-title><source>Neurology</source><year>2006</year><volume>67</volume><fpage>273</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000223832.66286.e4</pub-id><pub-id pub-id-type="pmid">16707726</pub-id>
</element-citation>
      </ref>
      <ref id="B51-jcm-13-05114">
        <label>51.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Owczarek-Lipska</surname><given-names>M.</given-names></name>
<name><surname>Mulahasanovic</surname><given-names>L.</given-names></name>
<name><surname>Obermaier</surname><given-names>C.D.</given-names></name>
<name><surname>H&#xF6;rtnagel</surname><given-names>K.</given-names></name>
<name><surname>Neubauer</surname><given-names>B.A.</given-names></name>
<name><surname>Korenke</surname><given-names>G.C.</given-names></name>
<name><surname>Biskup</surname><given-names>S.</given-names></name>
<name><surname>Neidhardt</surname><given-names>J.</given-names></name>
</person-group><article-title>Novel mutations in the GJC2 gene associated with Pelizaeus-Merzbacher-like disease</article-title><source>Mol. Biol. Rep.</source><year>2019</year><volume>46</volume><fpage>4507</fpage><lpage>4516</lpage><pub-id pub-id-type="doi">10.1007/s11033-019-04906-4</pub-id><pub-id pub-id-type="pmid">31270756</pub-id>
</element-citation>
      </ref>
      <ref id="B52-jcm-13-05114">
        <label>52.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kammoun Jellouli</surname><given-names>N.</given-names></name>
<name><surname>Salem</surname><given-names>I.H.</given-names></name>
<name><surname>Ellouz</surname><given-names>E.</given-names></name>
<name><surname>Louhichi</surname><given-names>N.</given-names></name>
<name><surname>Tlili</surname><given-names>A.</given-names></name>
<name><surname>Kammoun</surname><given-names>F.</given-names></name>
<name><surname>Triki</surname><given-names>C.</given-names></name>
<name><surname>Fakhfakh</surname><given-names>F.</given-names></name>
</person-group><article-title>Molecular confirmation of founder mutation c.-167A&gt;G in Tunisian patients with PMLD disease</article-title><source>Gene</source><year>2013</year><volume>513</volume><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2012.10.070</pub-id><pub-id pub-id-type="pmid">23142375</pub-id>
</element-citation>
      </ref>
      <ref id="B53-jcm-13-05114">
        <label>53.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yalcinkaya</surname><given-names>C.</given-names></name>
<name><surname>Erturk</surname><given-names>O.</given-names></name>
<name><surname>Tuysuz</surname><given-names>B.</given-names></name>
<name><surname>Yesil</surname><given-names>G.</given-names></name>
<name><surname>Verbeke</surname><given-names>J.I.</given-names></name>
<name><surname>Keyser</surname><given-names>B.</given-names></name>
<name><surname>Stuhrmann</surname><given-names>M.</given-names></name>
<name><surname>Steinemann</surname><given-names>D.</given-names></name>
<name><surname>Sistermans</surname><given-names>E.A.</given-names></name>
<name><surname>van der Knaap</surname><given-names>M.S.</given-names></name>
</person-group><article-title>A novel GJC2 mutation associated with hypomyelination and M&#xFC;llerian agenesis syndrome: Coincidence or a new entity?</article-title><source>Neuropediatrics</source><year>2012</year><volume>43</volume><fpage>159</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1055/s-0032-1313912</pub-id><pub-id pub-id-type="pmid">22610664</pub-id>
</element-citation>
      </ref>
      <ref id="B54-jcm-13-05114">
        <label>54.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mercimek-Mahmutoglu</surname><given-names>S.</given-names></name>
<name><surname>van der Knaap</surname><given-names>M.S.</given-names></name>
<name><surname>Baric</surname><given-names>I.</given-names></name>
<name><surname>Prayer</surname><given-names>D.</given-names></name>
<name><surname>Stoeckler-Ipsiroglu</surname><given-names>S.</given-names></name>
</person-group><article-title>Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC). Report of a new case</article-title><source>Neuropediatrics</source><year>2005</year><volume>36</volume><fpage>223</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1055/s-2005-865715</pub-id><pub-id pub-id-type="pmid">15944912</pub-id>
</element-citation>
      </ref>
      <ref id="B55-jcm-13-05114">
        <label>55.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miyake</surname><given-names>N.</given-names></name>
<name><surname>Wolf</surname><given-names>N.I.</given-names></name>
<name><surname>Cayami</surname><given-names>F.K.</given-names></name>
<name><surname>Crawford</surname><given-names>J.</given-names></name>
<name><surname>Bley</surname><given-names>A.</given-names></name>
<name><surname>Bulas</surname><given-names>D.</given-names></name>
<name><surname>Conant</surname><given-names>A.</given-names></name>
<name><surname>Bent</surname><given-names>S.J.</given-names></name>
<name><surname>Gripp</surname><given-names>K.W.</given-names></name>
<name><surname>Hahn</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>X-linked hypomyelination with spondylometaphyseal dysplasia (H-SMD) associated with mutations in AIFM1</article-title><source>Neurogenetics</source><year>2017</year><volume>18</volume><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1007/s10048-017-0520-x</pub-id><pub-id pub-id-type="pmid">28842795</pub-id>
</element-citation>
      </ref>
      <ref id="B56-jcm-13-05114">
        <label>56.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Helman</surname><given-names>G.</given-names></name>
<name><surname>Zerem</surname><given-names>A.</given-names></name>
<name><surname>Almad</surname><given-names>A.</given-names></name>
<name><surname>Hacker</surname><given-names>J.L.</given-names></name>
<name><surname>Woidill</surname><given-names>S.</given-names></name>
<name><surname>Sase</surname><given-names>S.</given-names></name>
<name><surname>LeFevre</surname><given-names>A.N.</given-names></name>
<name><surname>Ekstein</surname><given-names>J.</given-names></name>
<name><surname>Johansson</surname><given-names>M.M.</given-names></name>
<name><surname>Stutterd</surname><given-names>C.A.</given-names></name>
<etal/>
</person-group><article-title>Further Delineation of the Clinical and Pathologic Features of HIKESHI-Related Hypomyelinating Leukodystrophy</article-title><source>Pediatr. Neurol.</source><year>2021</year><volume>121</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2021.04.014</pub-id><pub-id pub-id-type="pmid">34111619</pub-id>
</element-citation>
      </ref>
      <ref id="B57-jcm-13-05114">
        <label>57.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Otero-Dominguez</surname><given-names>E.</given-names></name>
<name><surname>Gomez-Lado</surname><given-names>C.</given-names></name>
<name><surname>Fuentes-Pita</surname><given-names>P.</given-names></name>
<name><surname>Dacruz</surname><given-names>D.</given-names></name>
<name><surname>Barros-Angueira</surname><given-names>F.</given-names></name>
<name><surname>Eiris-Punal</surname><given-names>J.</given-names></name>
</person-group><article-title>[Hypomyelinating leukodystrophy type 6. Clinical and neuroimaging key features in the detection of a new case]</article-title><source>Rev. Neurol.</source><year>2018</year><volume>67</volume><fpage>339</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">30350845</pub-id>
</element-citation>
      </ref>
      <ref id="B58-jcm-13-05114">
        <label>58.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Numata</surname><given-names>Y.</given-names></name>
<name><surname>Gotoh</surname><given-names>L.</given-names></name>
<name><surname>Iwaki</surname><given-names>A.</given-names></name>
<name><surname>Kurosawa</surname><given-names>K.</given-names></name>
<name><surname>Takanashi</surname><given-names>J.</given-names></name>
<name><surname>Deguchi</surname><given-names>K.</given-names></name>
<name><surname>Yamamoto</surname><given-names>T.</given-names></name>
<name><surname>Osaka</surname><given-names>H.</given-names></name>
<name><surname>Inoue</surname><given-names>K.</given-names></name>
</person-group><article-title>Epidemiological, clinical, and genetic landscapes of hypomyelinating leukodystrophies</article-title><source>J. Neurol.</source><year>2014</year><volume>261</volume><fpage>752</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1007/s00415-014-7263-5</pub-id><pub-id pub-id-type="pmid">24532200</pub-id>
</element-citation>
      </ref>
      <ref id="B59-jcm-13-05114">
        <label>59.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bassani</surname><given-names>R.</given-names></name>
<name><surname>Pareyson</surname><given-names>D.</given-names></name>
<name><surname>D&#x2019;Incerti</surname><given-names>L.</given-names></name>
<name><surname>Di Bella</surname><given-names>D.</given-names></name>
<name><surname>Taroni</surname><given-names>F.</given-names></name>
<name><surname>Salsano</surname><given-names>E.</given-names></name>
</person-group><article-title>Pendular nystagmus in hypomyelinating leukodystrophy</article-title><source>J. Clin. Neurosci.</source><year>2013</year><volume>20</volume><fpage>1443</fpage><lpage>1445</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2012.11.014</pub-id><pub-id pub-id-type="pmid">23845262</pub-id>
</element-citation>
      </ref>
      <ref id="B60-jcm-13-05114">
        <label>60.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blumkin</surname><given-names>L.</given-names></name>
<name><surname>Lev</surname><given-names>D.</given-names></name>
<name><surname>Watemberg</surname><given-names>N.</given-names></name>
<name><surname>Lerman-Sagie</surname><given-names>T.</given-names></name>
</person-group><article-title>Hypomyelinating leukoencephalopathy with paroxysmal tonic upgaze and absence of psychomotor development</article-title><source>Mov. Disord.</source><year>2007</year><volume>22</volume><fpage>226</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1002/mds.21277</pub-id><pub-id pub-id-type="pmid">17149740</pub-id>
</element-citation>
      </ref>
      <ref id="B61-jcm-13-05114">
        <label>61.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamanaka</surname><given-names>K.</given-names></name>
<name><surname>Miyatake</surname><given-names>S.</given-names></name>
<name><surname>Zerem</surname><given-names>A.</given-names></name>
<name><surname>Lev</surname><given-names>D.</given-names></name>
<name><surname>Blumkin</surname><given-names>L.</given-names></name>
<name><surname>Yokochi</surname><given-names>K.</given-names></name>
<name><surname>Fujita</surname><given-names>A.</given-names></name>
<name><surname>Imagawa</surname><given-names>E.</given-names></name>
<name><surname>Iwama</surname><given-names>K.</given-names></name>
<name><surname>Nakashima</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Expanding the phenotype of IBA57 mutations: Related leukodystrophy can remain asymptomatic</article-title><source>J. Hum. Genet.</source><year>2018</year><volume>63</volume><fpage>1223</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1038/s10038-018-0516-x</pub-id><pub-id pub-id-type="pmid">30258207</pub-id>
</element-citation>
      </ref>
      <ref id="B62-jcm-13-05114">
        <label>62.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alfadhel</surname><given-names>M.</given-names></name>
<name><surname>Nashabat</surname><given-names>M.</given-names></name>
<name><surname>Alrifai</surname><given-names>M.T.</given-names></name>
<name><surname>Alshaalan</surname><given-names>H.</given-names></name>
<name><surname>Al Mutairi</surname><given-names>F.</given-names></name>
<name><surname>Al-Shahrani</surname><given-names>S.A.</given-names></name>
<name><surname>Plecko</surname><given-names>B.</given-names></name>
<name><surname>Almass</surname><given-names>R.</given-names></name>
<name><surname>Alsagob</surname><given-names>M.</given-names></name>
<name><surname>Almutairi</surname><given-names>F.B.</given-names></name>
<etal/>
</person-group><article-title>Further delineation of the phenotypic spectrum of ISCA2 defect: A report of ten new cases</article-title><source>Eur. J. Paediatr. Neurol.</source><year>2018</year><volume>22</volume><fpage>46</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.ejpn.2017.10.003</pub-id><pub-id pub-id-type="pmid">29122497</pub-id>
</element-citation>
      </ref>
      <ref id="B63-jcm-13-05114">
        <label>63.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alaimo</surname><given-names>J.T.</given-names></name>
<name><surname>Besse</surname><given-names>A.</given-names></name>
<name><surname>Alston</surname><given-names>C.L.</given-names></name>
<name><surname>Pang</surname><given-names>K.</given-names></name>
<name><surname>Appadurai</surname><given-names>V.</given-names></name>
<name><surname>Samanta</surname><given-names>M.</given-names></name>
<name><surname>Smpokou</surname><given-names>P.</given-names></name>
<name><surname>McFarland</surname><given-names>R.</given-names></name>
<name><surname>Taylor</surname><given-names>R.W.</given-names></name>
<name><surname>Bonnen</surname><given-names>P.E.</given-names></name>
</person-group><article-title>Loss-of-function mutations in ISCA2 disrupt 4Fe-4S cluster machinery and cause a fatal leukodystrophy with hyperglycinemia and mtDNA depletion</article-title><source>Hum. Mutat.</source><year>2018</year><volume>39</volume><fpage>537</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1002/humu.23396</pub-id><pub-id pub-id-type="pmid">29297947</pub-id>
</element-citation>
      </ref>
      <ref id="B64-jcm-13-05114">
        <label>64.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toldo</surname><given-names>I.</given-names></name>
<name><surname>Nosadini</surname><given-names>M.</given-names></name>
<name><surname>Boscardin</surname><given-names>C.</given-names></name>
<name><surname>Talenti</surname><given-names>G.</given-names></name>
<name><surname>Manara</surname><given-names>R.</given-names></name>
<name><surname>Lamantea</surname><given-names>E.</given-names></name>
<name><surname>Legati</surname><given-names>A.</given-names></name>
<name><surname>Ghezzi</surname><given-names>D.</given-names></name>
<name><surname>Perilongo</surname><given-names>G.</given-names></name>
<name><surname>Sartori</surname><given-names>S.</given-names></name>
</person-group><article-title>Neonatal mitochondrial leukoencephalopathy with brain and spinal involvement and high lactate: Expanding the phenotype of ISCA2 gene mutations</article-title><source>Metab. Brain Dis.</source><year>2018</year><volume>33</volume><fpage>805</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1007/s11011-017-0181-3</pub-id><pub-id pub-id-type="pmid">29359243</pub-id>
</element-citation>
      </ref>
      <ref id="B65-jcm-13-05114">
        <label>65.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Itoh</surname><given-names>M.</given-names></name>
<name><surname>Dai</surname><given-names>H.</given-names></name>
<name><surname>Horike</surname><given-names>S.I.</given-names></name>
<name><surname>Gonzalez</surname><given-names>J.</given-names></name>
<name><surname>Kitami</surname><given-names>Y.</given-names></name>
<name><surname>Meguro-Horike</surname><given-names>M.</given-names></name>
<name><surname>Kuki</surname><given-names>I.</given-names></name>
<name><surname>Shimakawa</surname><given-names>S.</given-names></name>
<name><surname>Yoshinaga</surname><given-names>H.</given-names></name>
<name><surname>Ota</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Biallelic KARS pathogenic variants cause an early-onset progressive leukodystrophy</article-title><source>Brain</source><year>2019</year><volume>142</volume><fpage>560</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1093/brain/awz001</pub-id><pub-id pub-id-type="pmid">30715177</pub-id>
</element-citation>
      </ref>
      <ref id="B66-jcm-13-05114">
        <label>66.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ardissone</surname><given-names>A.</given-names></name>
<name><surname>Tonduti</surname><given-names>D.</given-names></name>
<name><surname>Legati</surname><given-names>A.</given-names></name>
<name><surname>Lamantea</surname><given-names>E.</given-names></name>
<name><surname>Barone</surname><given-names>R.</given-names></name>
<name><surname>Dorboz</surname><given-names>I.</given-names></name>
<name><surname>Boespflug-Tanguy</surname><given-names>O.</given-names></name>
<name><surname>Nebbia</surname><given-names>G.</given-names></name>
<name><surname>Maggioni</surname><given-names>M.</given-names></name>
<name><surname>Garavaglia</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>KARS-related diseases: Progressive leukoencephalopathy with brainstem and spinal cord calcifications as new phenotype and a review of literature</article-title><source>Orphanet J. Rare Dis.</source><year>2018</year><volume>13</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/s13023-018-0788-4</pub-id><pub-id pub-id-type="pmid">29615062</pub-id>
</element-citation>
      </ref>
      <ref id="B67-jcm-13-05114">
        <label>67.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laxdal</surname><given-names>T.</given-names></name>
<name><surname>Hallgrimsson</surname><given-names>J.</given-names></name>
</person-group><article-title>Krabbe&#x2019;s globoid cell leucodystrophy with hydrocephalus</article-title><source>Arch. Dis. Child.</source><year>1974</year><volume>49</volume><fpage>232</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1136/adc.49.3.232</pub-id><pub-id pub-id-type="pmid">4825629</pub-id>
</element-citation>
      </ref>
      <ref id="B68-jcm-13-05114">
        <label>68.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bascou</surname><given-names>N.</given-names></name>
<name><surname>DeRenzo</surname><given-names>A.</given-names></name>
<name><surname>Poe</surname><given-names>M.D.</given-names></name>
<name><surname>Escolar</surname><given-names>M.L.</given-names></name>
</person-group><article-title>A prospective natural history study of Krabbe disease in a patient cohort with onset between 6 months and 3 years of life</article-title><source>Orphanet J. Rare Dis.</source><year>2018</year><volume>13</volume><fpage>126</fpage><pub-id pub-id-type="doi">10.1186/s13023-018-0872-9</pub-id><pub-id pub-id-type="pmid">30089515</pub-id>
</element-citation>
      </ref>
      <ref id="B69-jcm-13-05114">
        <label>69.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bussi&#xE8;re</surname><given-names>M.</given-names></name>
<name><surname>Kotylak</surname><given-names>T.</given-names></name>
<name><surname>Naik</surname><given-names>K.</given-names></name>
<name><surname>Levin</surname><given-names>S.</given-names></name>
</person-group><article-title>Optic nerve enlargement associated with globoid cell leukodystrophy</article-title><source>Can. J. Neurol. Sci.</source><year>2006</year><volume>33</volume><fpage>235</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1017/S0317167100005047</pub-id><pub-id pub-id-type="pmid">16736737</pub-id>
</element-citation>
      </ref>
      <ref id="B70-jcm-13-05114">
        <label>70.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roy</surname><given-names>P.</given-names></name>
<name><surname>Chidambaranathan</surname><given-names>S.</given-names></name>
<name><surname>Ramesh</surname><given-names>S.</given-names></name>
</person-group><article-title>Krabbe disease--a case report</article-title><source>J. Indian. Med. Assoc.</source><year>2005</year><volume>103</volume><fpage>548</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">16498763</pub-id>
</element-citation>
      </ref>
      <ref id="B71-jcm-13-05114">
        <label>71.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arvidsson</surname><given-names>J.</given-names></name>
<name><surname>Hagberg</surname><given-names>B.</given-names></name>
<name><surname>M&#xE5;nsson</surname><given-names>J.E.</given-names></name>
<name><surname>Svennerholm</surname><given-names>L.</given-names></name>
</person-group><article-title>Late onset globoid cell leukodystrophy (Krabbe&#x2019;s disease)--Swedish case with 15 years of follow-up</article-title><source>Acta Paediatr.</source><year>1995</year><volume>84</volume><fpage>218</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1111/j.1651-2227.1995.tb13616.x</pub-id><pub-id pub-id-type="pmid">7756815</pub-id>
</element-citation>
      </ref>
      <ref id="B72-jcm-13-05114">
        <label>72.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bascou</surname><given-names>N.A.</given-names></name>
<name><surname>Beltran-Quintero</surname><given-names>M.L.</given-names></name>
<name><surname>Escolar</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Pathogenic Variants in GALC Gene Correlate With Late Onset Krabbe Disease and Vision Loss: Case Series and Review of Literature</article-title><source>Front. Neurol.</source><year>2020</year><volume>11</volume><elocation-id>563724</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2020.563724</pub-id><pub-id pub-id-type="pmid">33178108</pub-id>
</element-citation>
      </ref>
      <ref id="B73-jcm-13-05114">
        <label>73.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lossos</surname><given-names>A.</given-names></name>
<name><surname>Elazar</surname><given-names>N.</given-names></name>
<name><surname>Lerer</surname><given-names>I.</given-names></name>
<name><surname>Schueler-Furman</surname><given-names>O.</given-names></name>
<name><surname>Fellig</surname><given-names>Y.</given-names></name>
<name><surname>Glick</surname><given-names>B.</given-names></name>
<name><surname>Zimmerman</surname><given-names>B.E.</given-names></name>
<name><surname>Azulay</surname><given-names>H.</given-names></name>
<name><surname>Dotan</surname><given-names>S.</given-names></name>
<name><surname>Goldberg</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Myelin-associated glycoprotein gene mutation causes Pelizaeus-Merzbacher disease-like disorder</article-title><source>Brain</source><year>2015</year><volume>138</volume><fpage>2521</fpage><lpage>2536</lpage><pub-id pub-id-type="doi">10.1093/brain/awv204</pub-id><pub-id pub-id-type="pmid">26179919</pub-id>
</element-citation>
      </ref>
      <ref id="B74-jcm-13-05114">
        <label>74.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roda</surname><given-names>R.H.</given-names></name>
<name><surname>FitzGibbon</surname><given-names>E.J.</given-names></name>
<name><surname>Boucekkine</surname><given-names>H.</given-names></name>
<name><surname>Schindler</surname><given-names>A.B.</given-names></name>
<name><surname>Blackstone</surname><given-names>C.</given-names></name>
</person-group><article-title>Neurologic syndrome associated with homozygous mutation at MAG sialic acid binding site</article-title><source>Ann. Clin. Transl. Neurol.</source><year>2016</year><volume>3</volume><fpage>650</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1002/acn3.329</pub-id><pub-id pub-id-type="pmid">27606346</pub-id>
</element-citation>
      </ref>
      <ref id="B75-jcm-13-05114">
        <label>75.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scmidt-Sidor</surname><given-names>B.</given-names></name>
<name><surname>Szyma&#x144;ska</surname><given-names>K.</given-names></name>
<name><surname>Lewandowska</surname><given-names>E.</given-names></name>
<name><surname>Mierzewska</surname><given-names>H.</given-names></name>
<name><surname>Wierzba-Bobrowicz</surname><given-names>T.</given-names></name>
<name><surname>Pasennik</surname><given-names>E.</given-names></name>
<name><surname>Stepie&#x144;</surname><given-names>T.</given-names></name>
</person-group><article-title>Infantile mitochondrial leucodystrophy&#x2014;A case report</article-title><source>Folia Neuropathol.</source><year>2005</year><volume>43</volume><fpage>186</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">16245215</pub-id>
</element-citation>
      </ref>
      <ref id="B76-jcm-13-05114">
        <label>76.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shian</surname><given-names>W.J.</given-names></name>
<name><surname>Chi</surname><given-names>C.C.</given-names></name>
<name><surname>Mak</surname><given-names>S.C.</given-names></name>
<name><surname>Tzeng</surname><given-names>G.Y.</given-names></name>
</person-group><article-title>Late infantile form metachromatic leukodystrophy: Report of one case</article-title><source>Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi</source><year>1992</year><volume>33</volume><fpage>286</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">1296437</pub-id>
</element-citation>
      </ref>
      <ref id="B77-jcm-13-05114">
        <label>77.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beerepoot</surname><given-names>S.</given-names></name>
<name><surname>Wolf</surname><given-names>N.I.</given-names></name>
<name><surname>Wehner</surname><given-names>K.</given-names></name>
<name><surname>Bender</surname><given-names>B.</given-names></name>
<name><surname>van der Knaap</surname><given-names>M.S.</given-names></name>
<name><surname>Kr&#xE4;geloh-Mann</surname><given-names>I.</given-names></name>
<name><surname>Groeschel</surname><given-names>S.</given-names></name>
</person-group><article-title>Acute-onset paralytic strabismus in toddlers is important to consider as a potential early sign of late-infantile Metachromatic Leukodystrophy</article-title><source>Eur. J. Paediatr. Neurol.</source><year>2022</year><volume>37</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.ejpn.2022.01.020</pub-id><pub-id pub-id-type="pmid">35152000</pub-id>
</element-citation>
      </ref>
      <ref id="B78-jcm-13-05114">
        <label>78.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kori</surname><given-names>A.A.</given-names></name>
<name><surname>Robin</surname><given-names>N.H.</given-names></name>
<name><surname>Jacobs</surname><given-names>J.B.</given-names></name>
<name><surname>Erchul</surname><given-names>D.M.</given-names></name>
<name><surname>Zaidat</surname><given-names>O.O.</given-names></name>
<name><surname>Remler</surname><given-names>B.F.</given-names></name>
<name><surname>Averbuch-Heller</surname><given-names>L.</given-names></name>
<name><surname>Dell&#x2019;Osso</surname><given-names>L.F.</given-names></name>
<name><surname>Leigh</surname><given-names>R.J.</given-names></name>
<name><surname>Zinn</surname><given-names>A.B.</given-names></name>
</person-group><article-title>Pendular nystagmus in patients with peroxisomal assembly disorder</article-title><source>Arch. Neurol.</source><year>1998</year><volume>55</volume><fpage>554</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1001/archneur.55.4.554</pub-id><pub-id pub-id-type="pmid">9561985</pub-id>
</element-citation>
      </ref>
      <ref id="B79-jcm-13-05114">
        <label>79.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hosseini Bereshneh</surname><given-names>A.</given-names></name>
<name><surname>Hosseipour</surname><given-names>S.</given-names></name>
<name><surname>Rasoulinezhad</surname><given-names>M.S.</given-names></name>
<name><surname>Pak</surname><given-names>N.</given-names></name>
<name><surname>Garshasbi</surname><given-names>M.</given-names></name>
<name><surname>Tavasoli</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Expanding the clinical and neuroimaging features of NKX6-2-related hereditary spastic ataxia type 8</article-title><source>Eur. J. Med. Genet.</source><year>2020</year><volume>63</volume><fpage>103868</fpage><pub-id pub-id-type="doi">10.1016/j.ejmg.2020.103868</pub-id><pub-id pub-id-type="pmid">32004679</pub-id>
</element-citation>
      </ref>
      <ref id="B80-jcm-13-05114">
        <label>80.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dorboz</surname><given-names>I.</given-names></name>
<name><surname>Aiello</surname><given-names>C.</given-names></name>
<name><surname>Simons</surname><given-names>C.</given-names></name>
<name><surname>Stone</surname><given-names>R.T.</given-names></name>
<name><surname>Niceta</surname><given-names>M.</given-names></name>
<name><surname>Elmaleh</surname><given-names>M.</given-names></name>
<name><surname>Abuawad</surname><given-names>M.</given-names></name>
<name><surname>Doummar</surname><given-names>D.</given-names></name>
<name><surname>Bruselles</surname><given-names>A.</given-names></name>
<name><surname>Wolf</surname><given-names>N.I.</given-names></name>
<etal/>
</person-group><article-title>Biallelic mutations in the homeodomain of NKX6-2 underlie a severe hypomyelinating leukodystrophy</article-title><source>Brain</source><year>2017</year><volume>140</volume><fpage>2550</fpage><lpage>2556</lpage><pub-id pub-id-type="doi">10.1093/brain/awx207</pub-id><pub-id pub-id-type="pmid">28969374</pub-id>
</element-citation>
      </ref>
      <ref id="B81-jcm-13-05114">
        <label>81.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chelban</surname><given-names>V.</given-names></name>
<name><surname>Alsagob</surname><given-names>M.</given-names></name>
<name><surname>Kloth</surname><given-names>K.</given-names></name>
<name><surname>Chirita-Emandi</surname><given-names>A.</given-names></name>
<name><surname>Vandrovcova</surname><given-names>J.</given-names></name>
<name><surname>Maroofian</surname><given-names>R.</given-names></name>
<name><surname>Davagnanam</surname><given-names>I.</given-names></name>
<name><surname>Bakhtiari</surname><given-names>S.</given-names></name>
<name><surname>AlSayed</surname><given-names>M.D.</given-names></name>
<name><surname>Rahbeeni</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Genetic and phenotypic characterization of NKX6-2-related spastic ataxia and hypomyelination</article-title><source>Eur. J. Neurol.</source><year>2020</year><volume>27</volume><fpage>334</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1111/ene.14082</pub-id><pub-id pub-id-type="pmid">31509304</pub-id>
</element-citation>
      </ref>
      <ref id="B82-jcm-13-05114">
        <label>82.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fu</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
</person-group><article-title>Novel Mutations in NPC1 are Associated with Pelizaeus-Merzbacher-Like Disease: A Case Report</article-title><source>Int. J. Gen. Med.</source><year>2021</year><volume>14</volume><fpage>797</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.2147/IJGM.S293675</pub-id><pub-id pub-id-type="pmid">33727856</pub-id>
</element-citation>
      </ref>
      <ref id="B83-jcm-13-05114">
        <label>83.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bae</surname><given-names>E.Y.</given-names></name>
<name><surname>Yi</surname><given-names>Y.</given-names></name>
<name><surname>Lim</surname><given-names>H.H.</given-names></name>
<name><surname>Lee</surname><given-names>J.M.</given-names></name>
<name><surname>Lee</surname><given-names>B.</given-names></name>
<name><surname>Kim</surname><given-names>S.Y.</given-names></name>
<name><surname>Kim</surname><given-names>Y.M.</given-names></name>
</person-group><article-title>First Case of Peroxisomal D-bifunctional Protein Deficiency with Novel HSD17B4 Mutations and Progressive Neuropathy in Korea</article-title><source>J. Korean Med. Sci.</source><year>2020</year><volume>35</volume><fpage>e357</fpage><pub-id pub-id-type="doi">10.3346/jkms.2020.35.e357</pub-id><pub-id pub-id-type="pmid">33045774</pub-id>
</element-citation>
      </ref>
      <ref id="B84-jcm-13-05114">
        <label>84.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Poll-The</surname><given-names>B.T.</given-names></name>
<name><surname>Gootjes</surname><given-names>J.</given-names></name>
<name><surname>Duran</surname><given-names>M.</given-names></name>
<name><surname>De Klerk</surname><given-names>J.B.</given-names></name>
<name><surname>Wenniger-Prick</surname><given-names>L.J.</given-names></name>
<name><surname>Admiraal</surname><given-names>R.J.</given-names></name>
<name><surname>Waterham</surname><given-names>H.R.</given-names></name>
<name><surname>Wanders</surname><given-names>R.J.</given-names></name>
<name><surname>Barth</surname><given-names>P.G.</given-names></name>
</person-group>
          <article-title>Peroxisome biogenesis disorders with prolonged survival: Phenotypic expression in a cohort of 31 patients</article-title>
          <source>Am. J. Med. Genet. A</source>
          <year>2004</year>
          <volume>126</volume>
          <fpage>333</fpage>
          <lpage>338</lpage>
          <pub-id pub-id-type="doi">10.1002/ajmg.a.20664</pub-id>
        </element-citation>
      </ref>
      <ref id="B85-jcm-13-05114">
        <label>85.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><article-title>Subacute onset leukodystrophy and visual-spatial disorders revealing phenylketonuria combined with homocysteinmia in adulthood: A case report</article-title><source>Medicine</source><year>2018</year><volume>97</volume><fpage>e9801</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000009801</pub-id><pub-id pub-id-type="pmid">29465562</pub-id>
</element-citation>
      </ref>
      <ref id="B86-jcm-13-05114">
        <label>86.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.H.</given-names></name>
<name><surname>Zhang</surname><given-names>H.F.</given-names></name>
<name><surname>Jin</surname><given-names>J.Y.</given-names></name>
<name><surname>Wei</surname><given-names>Y.Q.</given-names></name>
<name><surname>Wang</surname><given-names>C.Y.</given-names></name>
<name><surname>Fan</surname><given-names>L.L.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
</person-group><article-title>Case Report: A Homozygous Mutation (p.Y62X) of Phospholipase D3 May Lead to a New Leukoencephalopathy Syndrome</article-title><source>Front. Aging Neurosci.</source><year>2021</year><volume>13</volume><elocation-id>671296</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2021.671296</pub-id><pub-id pub-id-type="pmid">34267643</pub-id>
</element-citation>
      </ref>
      <ref id="B87-jcm-13-05114">
        <label>87.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nicita</surname><given-names>F.</given-names></name>
<name><surname>Aiello</surname><given-names>C.</given-names></name>
<name><surname>Vasco</surname><given-names>G.</given-names></name>
<name><surname>Valeriani</surname><given-names>M.</given-names></name>
<name><surname>Stregapede</surname><given-names>F.</given-names></name>
<name><surname>Sancesario</surname><given-names>A.</given-names></name>
<name><surname>Armando</surname><given-names>M.</given-names></name>
<name><surname>Bertini</surname><given-names>E.</given-names></name>
</person-group><article-title>Expanding the Clinical and Mutational Spectrum of the PLP1-Related Hypomyelination of Early Myelinated Structures (HEMS)</article-title><source>Brain Sci.</source><year>2021</year><volume>11</volume><elocation-id>93</elocation-id><pub-id pub-id-type="doi">10.3390/brainsci11010093</pub-id><pub-id pub-id-type="pmid">33450882</pub-id>
</element-citation>
      </ref>
      <ref id="B88-jcm-13-05114">
        <label>88.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Velasco Parra</surname><given-names>H.M.</given-names></name>
<name><surname>Maradei Anaya</surname><given-names>S.J.</given-names></name>
<name><surname>Acosta Guio</surname><given-names>J.C.</given-names></name>
<name><surname>Arteaga Diaz</surname><given-names>C.E.</given-names></name>
<name><surname>Prieto Rivera</surname><given-names>J.C.</given-names></name>
</person-group>
          <article-title>Clinical and mutational spectrum of Colombian patients with Pelizaeus Merzbacher Disease</article-title>
          <source>Colomb. Med.</source>
          <year>2018</year>
          <volume>49</volume>
          <fpage>182</fpage>
          <lpage>187</lpage>
          <pub-id pub-id-type="doi">10.25100/cm.v49i2.2522</pub-id>
        </element-citation>
      </ref>
      <ref id="B89-jcm-13-05114">
        <label>89.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Najafi</surname><given-names>K.</given-names></name>
<name><surname>Kariminejad</surname><given-names>R.</given-names></name>
<name><surname>Hosseini</surname><given-names>K.</given-names></name>
<name><surname>Moshtagh</surname><given-names>A.</given-names></name>
<name><surname>Abbassi</surname><given-names>G.M.</given-names></name>
<name><surname>Sadatian</surname><given-names>N.</given-names></name>
<name><surname>Bazrgar</surname><given-names>M.</given-names></name>
<name><surname>Kariminejad</surname><given-names>A.</given-names></name>
<name><surname>Kariminejad</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Familial Case of Pelizaeus-Merzbacher Disorder Detected by Oligoarray Comparative Genomic Hybridization: Genotype-to-Phenotype Diagnosis</article-title><source>Case Rep. Genet.</source><year>2017</year><volume>2017</volume><fpage>2706098</fpage><pub-id pub-id-type="doi">10.1155/2017/2706098</pub-id><pub-id pub-id-type="pmid">28133555</pub-id>
</element-citation>
      </ref>
      <ref id="B90-jcm-13-05114">
        <label>90.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.C.</given-names></name>
<name><surname>Liang</surname><given-names>W.C.</given-names></name>
<name><surname>Su</surname><given-names>Y.N.</given-names></name>
<name><surname>Jong</surname><given-names>Y.J.</given-names></name>
</person-group><article-title>Pelizaeus-Merzbacher disease, easily misdiagnosed as cerebral palsy: A report of a three-generation family</article-title><source>Pediatr. Neonatol.</source><year>2014</year><volume>55</volume><fpage>150</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.pedneo.2012.12.006</pub-id><pub-id pub-id-type="pmid">23597542</pub-id>
</element-citation>
      </ref>
      <ref id="B91-jcm-13-05114">
        <label>91.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shimojima</surname><given-names>K.</given-names></name>
<name><surname>Mano</surname><given-names>T.</given-names></name>
<name><surname>Kashiwagi</surname><given-names>M.</given-names></name>
<name><surname>Tanabe</surname><given-names>T.</given-names></name>
<name><surname>Sugawara</surname><given-names>M.</given-names></name>
<name><surname>Okamoto</surname><given-names>N.</given-names></name>
<name><surname>Arai</surname><given-names>H.</given-names></name>
<name><surname>Yamamoto</surname><given-names>T.</given-names></name>
</person-group><article-title>Pelizaeus-Merzbacher disease caused by a duplication-inverted triplication-duplication in chromosomal segments including the PLP1 region</article-title><source>Eur. J. Med. Genet.</source><year>2012</year><volume>55</volume><fpage>400</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/j.ejmg.2012.02.013</pub-id><pub-id pub-id-type="pmid">22490426</pub-id>
</element-citation>
      </ref>
      <ref id="B92-jcm-13-05114">
        <label>92.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.J.</given-names></name>
<name><surname>Yoon</surname><given-names>J.S.</given-names></name>
<name><surname>Baek</surname><given-names>H.J.</given-names></name>
<name><surname>Suh</surname><given-names>S.I.</given-names></name>
<name><surname>Bae</surname><given-names>S.Y.</given-names></name>
<name><surname>Cho</surname><given-names>H.J.</given-names></name>
<name><surname>Ki</surname><given-names>C.S.</given-names></name>
</person-group><article-title>Identification of proteolipid protein 1 gene duplication by multiplex ligation-dependent probe amplification: First report of genetically confirmed family of Pelizaeus-Merzbacher disease in Korea</article-title><source>J. Korean Med. Sci.</source><year>2008</year><volume>23</volume><fpage>328</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.3346/jkms.2008.23.2.328</pub-id><pub-id pub-id-type="pmid">18437021</pub-id>
</element-citation>
      </ref>
      <ref id="B93-jcm-13-05114">
        <label>93.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nezu</surname><given-names>A.</given-names></name>
</person-group><article-title>Neurophysiological study in Pelizaeus-Merzbacher disease</article-title><source>Brain Dev.</source><year>1995</year><volume>17</volume><fpage>175</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/0387-7604(95)00028-A</pub-id><pub-id pub-id-type="pmid">7573756</pub-id>
</element-citation>
      </ref>
      <ref id="B94-jcm-13-05114">
        <label>94.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>Z.J.</given-names></name>
<name><surname>Jiang</surname><given-names>Q.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Xu</surname><given-names>K.M.</given-names></name>
<name><surname>Liu</surname><given-names>Z.Q.</given-names></name>
<name><surname>Chen</surname><given-names>X.B.</given-names></name>
<name><surname>Chen</surname><given-names>X.L.</given-names></name>
</person-group><article-title>Clinical manifestation and gene analyses of 15 patients with intellectual disability or developmental delay complicated with congenital nystagmus</article-title><source>Zhonghua Er Ke Za Zhi</source><year>2017</year><volume>55</volume><fpage>824</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.0578-1310.2017.11.007</pub-id><pub-id pub-id-type="pmid">29141312</pub-id>
</element-citation>
      </ref>
      <ref id="B95-jcm-13-05114">
        <label>95.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tewari</surname><given-names>V.V.</given-names></name>
<name><surname>Mehta</surname><given-names>R.</given-names></name>
<name><surname>Sreedhar</surname><given-names>C.M.</given-names></name>
<name><surname>Tewari</surname><given-names>K.</given-names></name>
<name><surname>Mohammad</surname><given-names>A.</given-names></name>
<name><surname>Gupta</surname><given-names>N.</given-names></name>
<name><surname>Gulati</surname><given-names>S.</given-names></name>
<name><surname>Kabra</surname><given-names>M.</given-names></name>
</person-group><article-title>A novel homozygous mutation in POLR3A gene causing 4H syndrome: A case report</article-title><source>BMC Pediatr.</source><year>2018</year><volume>18</volume><elocation-id>126</elocation-id><pub-id pub-id-type="doi">10.1186/s12887-018-1108-9</pub-id><pub-id pub-id-type="pmid">29618326</pub-id>
</element-citation>
      </ref>
      <ref id="B96-jcm-13-05114">
        <label>96.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uygun</surname><given-names>&#xD6;.</given-names></name>
<name><surname>G&#xFC;nd&#xFC;z</surname><given-names>T.</given-names></name>
<name><surname>Eraksoy</surname><given-names>M.</given-names></name>
<name><surname>K&#xFC;rt&#xFC;nc&#xFC;</surname><given-names>M.</given-names></name>
</person-group><article-title>Adult-onset 4H leukodystrophy: A case presentation and review of the literature</article-title><source>Acta Neurol. Belg.</source><year>2020</year><volume>120</volume><fpage>1461</fpage><lpage>1462</lpage><pub-id pub-id-type="doi">10.1007/s13760-020-01297-3</pub-id><pub-id pub-id-type="pmid">32052360</pub-id>
</element-citation>
      </ref>
      <ref id="B97-jcm-13-05114">
        <label>97.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rezaei</surname><given-names>Z.</given-names></name>
<name><surname>Hosseinpour</surname><given-names>S.</given-names></name>
<name><surname>Ashrafi</surname><given-names>M.R.</given-names></name>
<name><surname>Mahdieh</surname><given-names>N.</given-names></name>
<name><surname>Alizadeh</surname><given-names>H.</given-names></name>
<name><surname>Mohammadpour</surname><given-names>M.</given-names></name>
<name><surname>Khosroshahi</surname><given-names>N.</given-names></name>
<name><surname>Amanat</surname><given-names>M.</given-names></name>
<name><surname>Tavasoli</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Hypomyelinating Leukodystrophy with Spinal Cord Involvement Caused by a Novel Variant in RARS: Report of Two Unrelated Patients</article-title><source>Neuropediatrics</source><year>2019</year><volume>50</volume><fpage>130</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1055/s-0039-1679911</pub-id><pub-id pub-id-type="pmid">30791064</pub-id>
</element-citation>
      </ref>
      <ref id="B98-jcm-13-05114">
        <label>98.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mendes</surname><given-names>M.I.</given-names></name>
<name><surname>Green</surname><given-names>L.M.C.</given-names></name>
<name><surname>Bertini</surname><given-names>E.</given-names></name>
<name><surname>Tonduti</surname><given-names>D.</given-names></name>
<name><surname>Aiello</surname><given-names>C.</given-names></name>
<name><surname>Smith</surname><given-names>D.</given-names></name>
<name><surname>Salsano</surname><given-names>E.</given-names></name>
<name><surname>Beerepoot</surname><given-names>S.</given-names></name>
<name><surname>Hertecant</surname><given-names>J.</given-names></name>
<name><surname>von Spiczak</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>RARS1-related hypomyelinating leukodystrophy: Expanding the spectrum</article-title><source>Ann. Clin. Transl. Neurol.</source><year>2020</year><volume>7</volume><fpage>83</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1002/acn3.50960</pub-id><pub-id pub-id-type="pmid">31814314</pub-id>
</element-citation>
      </ref>
      <ref id="B99-jcm-13-05114">
        <label>99.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Acharya</surname><given-names>B.S.</given-names></name>
<name><surname>Ritwik</surname><given-names>P.</given-names></name>
<name><surname>Velasquez</surname><given-names>G.M.</given-names></name>
<name><surname>Fenton</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Medical-dental findings and management of a child with infantile Refsum disease: A case report</article-title><source>Spec. Care Dentist.</source><year>2012</year><volume>32</volume><fpage>112</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1111/j.1754-4505.2012.00248.x</pub-id><pub-id pub-id-type="pmid">22591434</pub-id>
</element-citation>
      </ref>
      <ref id="B100-jcm-13-05114">
        <label>100.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Llaci</surname><given-names>L.</given-names></name>
<name><surname>Ramsey</surname><given-names>K.</given-names></name>
<name><surname>Belnap</surname><given-names>N.</given-names></name>
<name><surname>Claasen</surname><given-names>A.M.</given-names></name>
<name><surname>Balak</surname><given-names>C.D.</given-names></name>
<name><surname>Szelinger</surname><given-names>S.</given-names></name>
<name><surname>Jepsen</surname><given-names>W.M.</given-names></name>
<name><surname>Siniard</surname><given-names>A.L.</given-names></name>
<name><surname>Richholt</surname><given-names>R.</given-names></name>
<name><surname>Izat</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Compound heterozygous mutations in SNAP29 is associated with Pelizaeus-Merzbacher-like disorder (PMLD)</article-title><source>Hum. Genet.</source><year>2019</year><volume>138</volume><fpage>1409</fpage><lpage>1417</lpage><pub-id pub-id-type="doi">10.1007/s00439-019-02077-7</pub-id><pub-id pub-id-type="pmid">31748968</pub-id>
</element-citation>
      </ref>
      <ref id="B101-jcm-13-05114">
        <label>101.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Simons</surname><given-names>C.</given-names></name>
<name><surname>Dyment</surname><given-names>D.</given-names></name>
<name><surname>Bent</surname><given-names>S.J.</given-names></name>
<name><surname>Crawford</surname><given-names>J.</given-names></name>
<name><surname>D&#x2019;Hooghe</surname><given-names>M.</given-names></name>
<name><surname>Kohlsch&#xFC;tter</surname><given-names>A.</given-names></name>
<name><surname>Venkateswaran</surname><given-names>S.</given-names></name>
<name><surname>Helman</surname><given-names>G.</given-names></name>
<name><surname>Poll-The</surname><given-names>B.T.</given-names></name>
<name><surname>Makowski</surname><given-names>C.C.</given-names></name>
<etal/>
</person-group><article-title>A recurrent de novo mutation in TMEM106B causes hypomyelinating leukodystrophy</article-title><source>Brain</source><year>2017</year><volume>140</volume><fpage>3105</fpage><lpage>3111</lpage><pub-id pub-id-type="doi">10.1093/brain/awx314</pub-id><pub-id pub-id-type="pmid">29186371</pub-id>
</element-citation>
      </ref>
      <ref id="B102-jcm-13-05114">
        <label>102.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ikemoto</surname><given-names>S.</given-names></name>
<name><surname>Hamano</surname><given-names>S.I.</given-names></name>
<name><surname>Kikuchi</surname><given-names>K.</given-names></name>
<name><surname>Koichihara</surname><given-names>R.</given-names></name>
<name><surname>Hirata</surname><given-names>Y.</given-names></name>
<name><surname>Matsuura</surname><given-names>R.</given-names></name>
<name><surname>Hiraide</surname><given-names>T.</given-names></name>
<name><surname>Nakashima</surname><given-names>M.</given-names></name>
<name><surname>Inoue</surname><given-names>K.</given-names></name>
<name><surname>Kurosawa</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>A recurrent TMEM106B mutation in hypomyelinating leukodystrophy: A rapid diagnostic assay</article-title><source>Brain Dev.</source><year>2020</year><volume>42</volume><fpage>603</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2020.06.002</pub-id><pub-id pub-id-type="pmid">32595021</pub-id>
</element-citation>
      </ref>
      <ref id="B103-jcm-13-05114">
        <label>103.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>H.</given-names></name>
<name><surname>Kubisiak</surname><given-names>T.</given-names></name>
<name><surname>Ji</surname><given-names>H.</given-names></name>
<name><surname>Xiao</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Burmeister</surname><given-names>M.</given-names></name>
</person-group><article-title>The recurrent mutation in TMEM106B also causes hypomyelinating leukodystrophy in China and is a CpG hotspot</article-title><source>Brain</source><year>2018</year><volume>141</volume><fpage>e36</fpage><pub-id pub-id-type="doi">10.1093/brain/awy029</pub-id><pub-id pub-id-type="pmid">29444210</pub-id>
</element-citation>
      </ref>
      <ref id="B104-jcm-13-05114">
        <label>104.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>H.</given-names></name>
<name><surname>Helman</surname><given-names>G.</given-names></name>
<name><surname>Murthy</surname><given-names>S.E.</given-names></name>
<name><surname>Ji</surname><given-names>H.</given-names></name>
<name><surname>Crawford</surname><given-names>J.</given-names></name>
<name><surname>Kubisiak</surname><given-names>T.</given-names></name>
<name><surname>Bent</surname><given-names>S.J.</given-names></name>
<name><surname>Xiao</surname><given-names>J.</given-names></name>
<name><surname>Taft</surname><given-names>R.J.</given-names></name>
<name><surname>Coombs</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Heterozygous Variants in the Mechanosensitive Ion Channel TMEM63A Result in Transient Hypomyelination during Infancy</article-title><source>Am. J. Hum. Genet.</source><year>2019</year><volume>105</volume><fpage>996</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2019.09.011</pub-id><pub-id pub-id-type="pmid">31587869</pub-id>
</element-citation>
      </ref>
      <ref id="B105-jcm-13-05114">
        <label>105.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stam</surname><given-names>A.H.</given-names></name>
<name><surname>Kothari</surname><given-names>P.H.</given-names></name>
<name><surname>Shaikh</surname><given-names>A.</given-names></name>
<name><surname>Gschwendter</surname><given-names>A.</given-names></name>
<name><surname>Jen</surname><given-names>J.C.</given-names></name>
<name><surname>Hodgkinson</surname><given-names>S.</given-names></name>
<name><surname>Hardy</surname><given-names>T.A.</given-names></name>
<name><surname>Hayes</surname><given-names>M.</given-names></name>
<name><surname>Kempster</surname><given-names>P.A.</given-names></name>
<name><surname>Kotschet</surname><given-names>K.E.</given-names></name>
<etal/>
</person-group><article-title>Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations</article-title><source>Brain</source><year>2016</year><volume>139</volume><fpage>2909</fpage><lpage>2922</lpage><pub-id pub-id-type="doi">10.1093/brain/aww217</pub-id><pub-id pub-id-type="pmid">27604306</pub-id>
</element-citation>
      </ref>
      <ref id="B106-jcm-13-05114">
        <label>106.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Purnell</surname><given-names>S.M.</given-names></name>
<name><surname>Bleyl</surname><given-names>S.B.</given-names></name>
<name><surname>Bonkowsky</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Clinical exome sequencing identifies a novel TUBB4A mutation in a child with static hypomyelinating leukodystrophy</article-title><source>Pediatr. Neurol.</source><year>2014</year><volume>50</volume><fpage>608</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2014.01.051</pub-id><pub-id pub-id-type="pmid">24742798</pub-id>
</element-citation>
      </ref>
      <ref id="B107-jcm-13-05114">
        <label>107.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Joyal</surname><given-names>K.M.</given-names></name>
<name><surname>Michaud</surname><given-names>J.</given-names></name>
<name><surname>van der Knaap</surname><given-names>M.S.</given-names></name>
<name><surname>Bugiani</surname><given-names>M.</given-names></name>
<name><surname>Venkateswaran</surname><given-names>S.</given-names></name>
</person-group><article-title>Severe TUBB4A-Related Hypomyelination With Atrophy of the Basal Ganglia and Cerebellum: Novel Neuropathological Findings</article-title><source>J. Neuropathol. Exp. Neurol.</source><year>2019</year><volume>78</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/jnen/nly105</pub-id><pub-id pub-id-type="pmid">30476126</pub-id>
</element-citation>
      </ref>
      <ref id="B108-jcm-13-05114">
        <label>108.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barros</surname><given-names>S.R.</given-names></name>
<name><surname>Parreira</surname><given-names>S.C.R.</given-names></name>
<name><surname>Miranda</surname><given-names>A.F.B.</given-names></name>
<name><surname>Pereira</surname><given-names>A.M.B.</given-names></name>
<name><surname>Campos</surname><given-names>N.M.P.</given-names></name>
</person-group><article-title>New Insights in Vanishing White Matter Disease: Isolated Bilateral Optic Neuropathy in Adult Onset Disease</article-title><source>J. Neuroophthalmol.</source><year>2018</year><volume>38</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1097/WNO.0000000000000565</pub-id><pub-id pub-id-type="pmid">28902089</pub-id>
</element-citation>
      </ref>
      <ref id="B109-jcm-13-05114">
        <label>109.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khorrami</surname><given-names>M.</given-names></name>
<name><surname>Khorram</surname><given-names>E.</given-names></name>
<name><surname>Yaghini</surname><given-names>O.</given-names></name>
<name><surname>Rezaei</surname><given-names>M.</given-names></name>
<name><surname>Hejazifar</surname><given-names>A.</given-names></name>
<name><surname>Iravani</surname><given-names>O.</given-names></name>
<name><surname>Yazdani</surname><given-names>V.</given-names></name>
<name><surname>Riahinezhad</surname><given-names>M.</given-names></name>
<name><surname>Kheirollahi</surname><given-names>M.</given-names></name>
</person-group><article-title>Identification of a Missense Variant in the EIF2B3 Gene Causing Vanishing White Matter Disease with Antenatal-Onset but Mild Symptoms and Long-Term Survival</article-title><source>J. Mol. Neurosci.</source><year>2021</year><volume>71</volume><fpage>2405</fpage><lpage>2414</lpage><pub-id pub-id-type="doi">10.1007/s12031-021-01810-0</pub-id><pub-id pub-id-type="pmid">33687620</pub-id>
</element-citation>
      </ref>
      <ref id="B110-jcm-13-05114">
        <label>110.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Powers</surname><given-names>J.M.</given-names></name>
<name><surname>Schaumburg</surname><given-names>H.H.</given-names></name>
</person-group><article-title>Adreno-leukodystrophy (sex-linked Schilder&#x2019;s disease). A pathogenetic hypothesis based on ultrastructural lesions in adrenal cortex, peripheral nerve and testis</article-title><source>Am. J. Pathol.</source><year>1974</year><volume>76</volume><fpage>481</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">4212914</pub-id>
</element-citation>
      </ref>
      <ref id="B111-jcm-13-05114">
        <label>111.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Battaglia</surname><given-names>A.</given-names></name>
<name><surname>Harden</surname><given-names>A.</given-names></name>
<name><surname>Pampiglione</surname><given-names>G.</given-names></name>
<name><surname>Walsh</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Adrenoleucodystrophy: Neurophysiological aspects</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><year>1981</year><volume>44</volume><fpage>781</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1136/jnnp.44.9.781</pub-id><pub-id pub-id-type="pmid">7310417</pub-id>
</element-citation>
      </ref>
      <ref id="B112-jcm-13-05114">
        <label>112.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zgorzalewicz-Stachowiak</surname><given-names>M.</given-names></name>
<name><surname>Stradomska</surname><given-names>T.J.</given-names></name>
<name><surname>Bartkowiak</surname><given-names>Z.</given-names></name>
<name><surname>Galas-Zgorzalewicz</surname><given-names>B.</given-names></name>
</person-group><article-title>Cerebral childhood and adolescent X-linked adrenoleukodystrophy. Clinical presentation, neurophysiological, neuroimaging and biochemical investigations</article-title><source>Folia Neuropathol.</source><year>2006</year><volume>44</volume><fpage>319</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">17183459</pub-id>
</element-citation>
      </ref>
      <ref id="B113-jcm-13-05114">
        <label>113.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sakurai</surname><given-names>K.</given-names></name>
<name><surname>Ohashi</surname><given-names>T.</given-names></name>
<name><surname>Shimozawa</surname><given-names>N.</given-names></name>
<name><surname>Joo-Hyun</surname><given-names>S.</given-names></name>
<name><surname>Okuyama</surname><given-names>T.</given-names></name>
<name><surname>Ida</surname><given-names>H.</given-names></name>
</person-group><article-title>Characteristics of Japanese patients with X-linked adrenoleukodystrophy and concerns of their families from the 1st registry system</article-title><source>Brain Dev.</source><year>2019</year><volume>41</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2018.07.007</pub-id><pub-id pub-id-type="pmid">30077509</pub-id>
</element-citation>
      </ref>
      <ref id="B114-jcm-13-05114">
        <label>114.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iinuma</surname><given-names>K.</given-names></name>
<name><surname>Haginoya</surname><given-names>K.</given-names></name>
<name><surname>Handa</surname><given-names>I.</given-names></name>
<name><surname>Kojima</surname><given-names>A.</given-names></name>
<name><surname>Fueki</surname><given-names>N.</given-names></name>
<name><surname>Aikawa</surname><given-names>J.</given-names></name>
<name><surname>Ito</surname><given-names>M.</given-names></name>
<name><surname>Hatazawa</surname><given-names>J.</given-names></name>
<name><surname>Ido</surname><given-names>T.</given-names></name>
</person-group><article-title>Computed tomography, magnetic resonance imaging, positron emission tomography and evoked potentials at early stage of adrenoleukodystrophy</article-title><source>Tohoku J. Exp. Med.</source><year>1989</year><volume>159</volume><fpage>195</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1620/tjem.159.195</pub-id><pub-id pub-id-type="pmid">2623662</pub-id>
</element-citation>
      </ref>
      <ref id="B115-jcm-13-05114">
        <label>115.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tur&#xF3;n-Vi&#xF1;as</surname><given-names>E.</given-names></name>
<name><surname>Pineda</surname><given-names>M.</given-names></name>
<name><surname>Cus&#xED;</surname><given-names>V.</given-names></name>
<name><surname>L&#xF3;pez-Laso</surname><given-names>E.</given-names></name>
<name><surname>Del Pozo</surname><given-names>R.L.</given-names></name>
<name><surname>Guti&#xE9;rrez-Solana</surname><given-names>L.G.</given-names></name>
<name><surname>Moreno</surname><given-names>D.C.</given-names></name>
<name><surname>Sierra-C&#xF3;rcoles</surname><given-names>C.</given-names></name>
<name><surname>Olabarrieta-Hoyos</surname><given-names>N.</given-names></name>
<name><surname>Madruga-Garrido</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Vanishing white matter disease in a spanish population</article-title><source>J. Cent. Nerv. Syst. Dis.</source><year>2014</year><volume>6</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.4137/JCNSD.S13540</pub-id><pub-id pub-id-type="pmid">25089094</pub-id>
</element-citation>
      </ref>
      <ref id="B116-jcm-13-05114">
        <label>116.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Traboulsi</surname><given-names>E.I.</given-names></name>
<name><surname>Maumenee</surname><given-names>I.H.</given-names></name>
</person-group><article-title>Ophthalmologic manifestations of X-linked childhood adrenoleukodystrophy</article-title><source>Ophthalmology</source><year>1987</year><volume>94</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/S0161-6420(87)33504-3</pub-id><pub-id pub-id-type="pmid">3561956</pub-id>
</element-citation>
      </ref>
      <ref id="B117-jcm-13-05114">
        <label>117.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jang</surname><given-names>Y.C.</given-names></name>
<name><surname>Mun</surname><given-names>B.R.</given-names></name>
<name><surname>Choi</surname><given-names>I.S.</given-names></name>
<name><surname>Song</surname><given-names>M.K.</given-names></name>
</person-group><article-title>Rehabilitative management of an infant with Pelizaeus-Merzbacher disease: A case report</article-title><source>Medicine (Baltimore)</source><year>2020</year><volume>99</volume><fpage>e20110</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000020110</pub-id><pub-id pub-id-type="pmid">32481377</pub-id>
</element-citation>
      </ref>
      <ref id="B118-jcm-13-05114">
        <label>118.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ueda</surname><given-names>A.</given-names></name>
<name><surname>Shimbo</surname><given-names>H.</given-names></name>
<name><surname>Yada</surname><given-names>Y.</given-names></name>
<name><surname>Koike</surname><given-names>Y.</given-names></name>
<name><surname>Yamagata</surname><given-names>T.</given-names></name>
<name><surname>Osaka</surname><given-names>H.</given-names></name>
</person-group><article-title>Pelizaeus-Merzbacher disease can be a differential diagnosis in males presenting with severe neonatal respiratory distress and hypotonia</article-title><source>Hum. Genome Var.</source><year>2018</year><volume>5</volume><fpage>18013</fpage><pub-id pub-id-type="doi">10.1038/hgv.2018.13</pub-id><pub-id pub-id-type="pmid">29619238</pub-id>
</element-citation>
      </ref>
      <ref id="B119-jcm-13-05114">
        <label>119.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Shimojima</surname><given-names>K.</given-names></name>
<name><surname>Sakuma</surname><given-names>T.</given-names></name>
<name><surname>Nakaoka</surname><given-names>S.</given-names></name>
<name><surname>Yamamoto</surname><given-names>T.</given-names></name>
</person-group><article-title>A novel PLP1 mutation F240L identified in a patient with connatal type Pelizaeus-Merzbacher disease</article-title><source>Hum. Genome Var.</source><year>2017</year><volume>4</volume><fpage>16044</fpage><pub-id pub-id-type="doi">10.1038/hgv.2016.44</pub-id><pub-id pub-id-type="pmid">28101371</pub-id>
</element-citation>
      </ref>
      <ref id="B120-jcm-13-05114">
        <label>120.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Masliah-Planchon</surname><given-names>J.</given-names></name>
<name><surname>Dupont</surname><given-names>C.</given-names></name>
<name><surname>Vartzelis</surname><given-names>G.</given-names></name>
<name><surname>Trimouille</surname><given-names>A.</given-names></name>
<name><surname>Eymard-Pierre</surname><given-names>E.</given-names></name>
<name><surname>Gay-Bellile</surname><given-names>M.</given-names></name>
<name><surname>Renaldo</surname><given-names>F.</given-names></name>
<name><surname>Dorboz</surname><given-names>I.</given-names></name>
<name><surname>Pagan</surname><given-names>C.</given-names></name>
<name><surname>Quentin</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Insertion of an extra copy of Xq22.2 into 1p36 results in functional duplication of the PLP1 gene in a girl with classical Pelizaeus-Merzbacher disease</article-title><source>BMC Med. Genet.</source><year>2015</year><volume>16</volume><elocation-id>77</elocation-id><pub-id pub-id-type="doi">10.1186/s12881-015-0226-6</pub-id><pub-id pub-id-type="pmid">26329556</pub-id>
</element-citation>
      </ref>
      <ref id="B121-jcm-13-05114">
        <label>121.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>H.</given-names></name>
<name><surname>Feng</surname><given-names>H.</given-names></name>
<name><surname>Ji</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Kou</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>D.</given-names></name>
<name><surname>Ji</surname><given-names>H.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Niu</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Identification and functional study of novel PLP1 mutations in Chinese patients with Pelizaeus-Merzbacher disease</article-title><source>Brain Dev.</source><year>2015</year><volume>37</volume><fpage>797</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2014.11.007</pub-id><pub-id pub-id-type="pmid">25491635</pub-id>
</element-citation>
      </ref>
      <ref id="B122-jcm-13-05114">
        <label>122.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shimojima</surname><given-names>K.</given-names></name>
<name><surname>Okumura</surname><given-names>A.</given-names></name>
<name><surname>Ikeno</surname><given-names>M.</given-names></name>
<name><surname>Nishimura</surname><given-names>A.</given-names></name>
<name><surname>Saito</surname><given-names>A.</given-names></name>
<name><surname>Saitsu</surname><given-names>H.</given-names></name>
<name><surname>Matsumoto</surname><given-names>N.</given-names></name>
<name><surname>Yamamoto</surname><given-names>T.</given-names></name>
</person-group><article-title>A de novo TUBB4A mutation in a patient with hypomyelination mimicking Pelizaeus-Merzbacher disease</article-title><source>Brain Dev.</source><year>2015</year><volume>37</volume><fpage>281</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2014.05.004</pub-id><pub-id pub-id-type="pmid">24974158</pub-id>
</element-citation>
      </ref>
      <ref id="B123-jcm-13-05114">
        <label>123.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naseebullah</surname></name>
<name><surname>Siddiqui</surname><given-names>M.</given-names></name>
<name><surname>Saeed</surname><given-names>S.</given-names></name>
<name><surname>Chaudary</surname><given-names>Y.</given-names></name>
</person-group><article-title>A rare case of Palizaeus Merzbacher Disease in a female patient diagnosed radiologically</article-title><source>J. Pak. Med. Assoc.</source><year>2014</year><volume>64</volume><fpage>1313</fpage><lpage>1314</lpage><pub-id pub-id-type="pmid">25831654</pub-id>
</element-citation>
      </ref>
      <ref id="B124-jcm-13-05114">
        <label>124.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karimzadeh</surname><given-names>P.</given-names></name>
<name><surname>Ahmadabadi</surname><given-names>F.</given-names></name>
<name><surname>Aryani</surname><given-names>O.</given-names></name>
<name><surname>Houshmand</surname><given-names>M.</given-names></name>
<name><surname>Khatami</surname><given-names>A.</given-names></name>
</person-group><article-title>New mutation of pelizaeus--merzbacher-like disease; a report from iran</article-title><source>Iran. J. Radiol.</source><year>2014</year><volume>11</volume><fpage>e6913</fpage><pub-id pub-id-type="doi">10.5812/iranjradiol.6913</pub-id><pub-id pub-id-type="pmid">25035705</pub-id>
</element-citation>
      </ref>
      <ref id="B125-jcm-13-05114">
        <label>125.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rikitake</surname><given-names>M.</given-names></name>
<name><surname>Kaga</surname><given-names>K.</given-names></name>
</person-group><article-title>Development of speech and hearing of two children with Pelizaeus-Merzbacher disease presenting only waves I and II of the auditory brainstem response</article-title><source>Acta Otolaryngol.</source><year>2012</year><volume>132</volume><fpage>563</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.3109/00016489.2011.647362</pub-id><pub-id pub-id-type="pmid">22264126</pub-id>
</element-citation>
      </ref>
      <ref id="B126-jcm-13-05114">
        <label>126.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shimojima</surname><given-names>K.</given-names></name>
<name><surname>Inoue</surname><given-names>T.</given-names></name>
<name><surname>Hoshino</surname><given-names>A.</given-names></name>
<name><surname>Kakiuchi</surname><given-names>S.</given-names></name>
<name><surname>Watanabe</surname><given-names>Y.</given-names></name>
<name><surname>Sasaki</surname><given-names>M.</given-names></name>
<name><surname>Nishimura</surname><given-names>A.</given-names></name>
<name><surname>Takeshita-Yanagisawa</surname><given-names>A.</given-names></name>
<name><surname>Tajima</surname><given-names>G.</given-names></name>
<name><surname>Ozawa</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Comprehensive genetic analyses of PLP1 in patients with Pelizaeus-Merzbacher disease applied by array-CGH and fiber-FISH analyses identified new mutations and variable sizes of duplications</article-title><source>Brain Dev.</source><year>2010</year><volume>32</volume><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2009.02.011</pub-id><pub-id pub-id-type="pmid">19328639</pub-id>
</element-citation>
      </ref>
      <ref id="B127-jcm-13-05114">
        <label>127.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kibe</surname><given-names>T.</given-names></name>
<name><surname>Miyahara</surname><given-names>J.</given-names></name>
<name><surname>Yokochi</surname><given-names>K.</given-names></name>
<name><surname>Iwaki</surname><given-names>A.</given-names></name>
</person-group><article-title>A novel PLP mutation in a Japanese patient with mild Pelizaeus-Merzbacher disease</article-title><source>Brain Dev.</source><year>2009</year><volume>31</volume><fpage>248</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2008.08.001</pub-id><pub-id pub-id-type="pmid">18783902</pub-id>
</element-citation>
      </ref>
      <ref id="B128-jcm-13-05114">
        <label>128.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.M.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>H.F.</given-names></name>
<name><surname>Deng</surname><given-names>Y.H.</given-names></name>
<name><surname>Yang</surname><given-names>Y.L.</given-names></name>
<name><surname>Qin</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>X.Y.</given-names></name>
<name><surname>Wu</surname><given-names>X.R.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.W.</given-names></name>
</person-group><article-title>Proteolipid protein 1 gene mutation in nine patients with Pelizaeus-Merzbacher disease</article-title><source>Chin. Med. J.</source><year>2008</year><volume>121</volume><fpage>1638</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1097/00029330-200809010-00008</pub-id><pub-id pub-id-type="pmid">19024090</pub-id>
</element-citation>
      </ref>
      <ref id="B129-jcm-13-05114">
        <label>129.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wolf</surname><given-names>N.I.</given-names></name>
<name><surname>Cundall</surname><given-names>M.</given-names></name>
<name><surname>Rutland</surname><given-names>P.</given-names></name>
<name><surname>Rosser</surname><given-names>E.</given-names></name>
<name><surname>Surtees</surname><given-names>R.</given-names></name>
<name><surname>Benton</surname><given-names>S.</given-names></name>
<name><surname>Chong</surname><given-names>W.K.</given-names></name>
<name><surname>Malcolm</surname><given-names>S.</given-names></name>
<name><surname>Ebinger</surname><given-names>F.</given-names></name>
<name><surname>Bitner-Glindzicz</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Frameshift mutation in GJA12 leading to nystagmus, spastic ataxia and CNS dys-/demyelination</article-title><source>Neurogenetics</source><year>2007</year><volume>8</volume><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1007/s10048-006-0062-0</pub-id><pub-id pub-id-type="pmid">16969684</pub-id>
</element-citation>
      </ref>
      <ref id="B130-jcm-13-05114">
        <label>130.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaga</surname><given-names>K.</given-names></name>
<name><surname>Tamai</surname><given-names>F.</given-names></name>
<name><surname>Kodama</surname><given-names>M.</given-names></name>
<name><surname>Kodama</surname><given-names>K.</given-names></name>
</person-group><article-title>Three young adult patients with Pelizaeus-Merzbacher disease who showed only waves I and II in auditory brainstem responses but had good auditory perception</article-title><source>Acta Otolaryngol.</source><year>2005</year><volume>125</volume><fpage>1018</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1080/00016480510038581</pub-id><pub-id pub-id-type="pmid">16193596</pub-id>
</element-citation>
      </ref>
      <ref id="B131-jcm-13-05114">
        <label>131.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Golomb</surname><given-names>M.R.</given-names></name>
<name><surname>Walsh</surname><given-names>L.E.</given-names></name>
<name><surname>Carvalho</surname><given-names>K.S.</given-names></name>
<name><surname>Christensen</surname><given-names>C.K.</given-names></name>
<name><surname>DeMyer</surname><given-names>W.E.</given-names></name>
</person-group><article-title>Clinical findings in Pelizaeus-Merzbacher disease</article-title><source>J. Child. Neurol.</source><year>2004</year><volume>19</volume><fpage>328</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1177/088307380401900504</pub-id><pub-id pub-id-type="pmid">15224705</pub-id>
</element-citation>
      </ref>
      <ref id="B132-jcm-13-05114">
        <label>132.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hobson</surname><given-names>G.M.</given-names></name>
<name><surname>Davis</surname><given-names>A.P.</given-names></name>
<name><surname>Stowell</surname><given-names>N.C.</given-names></name>
<name><surname>Kolodny</surname><given-names>E.H.</given-names></name>
<name><surname>Sistermans</surname><given-names>E.A.</given-names></name>
<name><surname>de Coo</surname><given-names>I.F.</given-names></name>
<name><surname>Funanage</surname><given-names>V.L.</given-names></name>
<name><surname>Marks</surname><given-names>H.G.</given-names></name>
</person-group><article-title>Mutations in noncoding regions of the proteolipid protein gene in Pelizaeus-Merzbacher disease</article-title><source>Neurology</source><year>2000</year><volume>55</volume><fpage>1089</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1212/WNL.55.8.1089</pub-id><pub-id pub-id-type="pmid">11071483</pub-id>
</element-citation>
      </ref>
      <ref id="B133-jcm-13-05114">
        <label>133.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moher</surname><given-names>D.</given-names></name>
<name><surname>Liberati</surname><given-names>A.</given-names></name>
<name><surname>Tetzlaff</surname><given-names>J.</given-names></name>
<name><surname>Altman</surname><given-names>D.G.</given-names></name>
<name><surname>The</surname><given-names>P.G.</given-names></name>
</person-group><article-title>Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement</article-title><source>PLOS Med.</source><year>2009</year><volume>6</volume><elocation-id>e1000097</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1000097</pub-id><pub-id pub-id-type="pmid">19621072</pub-id>
</element-citation>
      </ref>
      <ref id="B134-jcm-13-05114">
        <label>134.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Page</surname><given-names>M.J.</given-names></name>
<name><surname>McKenzie</surname><given-names>J.E.</given-names></name>
<name><surname>Bossuyt</surname><given-names>P.M.</given-names></name>
<name><surname>Boutron</surname><given-names>I.</given-names></name>
<name><surname>Hoffmann</surname><given-names>T.C.</given-names></name>
<name><surname>Mulrow</surname><given-names>C.D.</given-names></name>
<name><surname>Shamseer</surname><given-names>L.</given-names></name>
<name><surname>Tetzlaff</surname><given-names>J.M.</given-names></name>
<name><surname>Akl</surname><given-names>E.A.</given-names></name>
<name><surname>Brennan</surname><given-names>S.E.</given-names></name>
<etal/>
</person-group>
          <article-title>The PRISMA 2020 statement: An updated guideline for reporting systematic reviews</article-title>
          <source>bmj</source>
          <year>2021</year>
          <volume>372</volume>
        </element-citation>
      </ref>
      <ref id="B135-jcm-13-05114">
        <label>135.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leigh</surname><given-names>R.J.</given-names></name>
<name><surname>Zee</surname><given-names>D.S.</given-names></name>
</person-group><article-title>Eye movements of the blind</article-title><source>Invest. Ophthalmol. Vis. Sci.</source><year>1980</year><volume>19</volume><fpage>328</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">6965668</pub-id>
</element-citation>
      </ref>
      <ref id="B136-jcm-13-05114">
        <label>136.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brodsky</surname><given-names>M.C.</given-names></name>
<name><surname>Fray</surname><given-names>K.J.</given-names></name>
<name><surname>Glasier</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Perinatal cortical and subcortical visual loss: Mechanisms of injury and associated ophthalmologic signs</article-title><source>Ophthalmology</source><year>2002</year><volume>109</volume><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/S0161-6420(01)00849-1</pub-id><pub-id pub-id-type="pmid">11772585</pub-id>
</element-citation>
      </ref>
      <ref id="B137-jcm-13-05114">
        <label>137.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mallinson</surname><given-names>A.I.</given-names></name>
<name><surname>Longridge</surname><given-names>N.S.</given-names></name>
<name><surname>Dunn</surname><given-names>H.G.</given-names></name>
<name><surname>McCormick</surname><given-names>A.Q.</given-names></name>
</person-group><article-title>Vestibular studies in Pelizaeus-Merzbacher disease</article-title><source>J. Otolaryngol.</source><year>1983</year><volume>12</volume><fpage>361</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">6663662</pub-id>
</element-citation>
      </ref>
      <ref id="B138-jcm-13-05114">
        <label>138.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Strupp</surname><given-names>M.</given-names></name>
<name><surname>H&#xFC;fner</surname><given-names>K.</given-names></name>
<name><surname>Sandmann</surname><given-names>R.</given-names></name>
<name><surname>Zwergal</surname><given-names>A.</given-names></name>
<name><surname>Dieterich</surname><given-names>M.</given-names></name>
<name><surname>Jahn</surname><given-names>K.</given-names></name>
<name><surname>Brandt</surname><given-names>T.</given-names></name>
</person-group><article-title>Central oculomotor disturbances and nystagmus: A window into the brainstem and cerebellum</article-title><source>Dtsch. Arztebl. Int.</source><year>2011</year><volume>108</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.3238/arztebl.2011.0197</pub-id><pub-id pub-id-type="pmid">21505601</pub-id>
</element-citation>
      </ref>
      <ref id="B139-jcm-13-05114">
        <label>139.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Creel</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Visually evoked potentials</article-title><source>Handb. Clin. Neurol.</source><year>2019</year><volume>160</volume><fpage>501</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1016/b978-0-444-64032-1.00034-5</pub-id><pub-id pub-id-type="pmid">31277872</pub-id>
</element-citation>
      </ref>
      <ref id="B140-jcm-13-05114">
        <label>140.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
<name><surname>Heinen</surname><given-names>F.</given-names></name>
<name><surname>M&#xFC;ller-Felber</surname><given-names>W.</given-names></name>
</person-group>
          <article-title>Evozierte Potenziale im Kindesalter</article-title>
          <source>Evozierte Potenziale, Neurovegetative Diagnostik, Okulographie</source>
          <person-group person-group-type="editor">
<name><surname>Buchner</surname><given-names>H.</given-names></name>
</person-group>
          <publisher-name>Georg Thieme Verlag KG</publisher-name>
          <publisher-loc>Stuttgart, Germany</publisher-loc>
          <year>2005</year>
        </element-citation>
      </ref>
      <ref id="B141-jcm-13-05114">
        <label>141.</label>
        <element-citation publication-type="journal">
          <article-title>Magnetic Resonance of Myelination and Myelin Disorders, 3rd ed</article-title>
          <source>AJNR Am. J. Neuroradiol.</source>
          <year>2006</year>
          <volume>27</volume>
          <fpage>947</fpage>
          <lpage>948</lpage>
        </element-citation>
      </ref>
      <ref id="B142-jcm-13-05114">
        <label>142.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kang</surname><given-names>S.L.</given-names></name>
<name><surname>Shaikh</surname><given-names>A.G.</given-names></name>
<name><surname>Ghasia</surname><given-names>F.F.</given-names></name>
</person-group><article-title>Vergence and Strabismus in Neurodegenerative Disorders</article-title><source>Front. Neurol.</source><year>2018</year><volume>9</volume><elocation-id>299</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2018.00299</pub-id><pub-id pub-id-type="pmid">29867716</pub-id>
</element-citation>
      </ref>
      <ref id="B143-jcm-13-05114">
        <label>143.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Libert</surname><given-names>J.</given-names></name>
<name><surname>Van Hoof</surname><given-names>F.</given-names></name>
<name><surname>Toussaint</surname><given-names>D.</given-names></name>
<name><surname>Roozitalab</surname><given-names>H.</given-names></name>
<name><surname>Kenyon</surname><given-names>K.R.</given-names></name>
<name><surname>Green</surname><given-names>W.R.</given-names></name>
</person-group><article-title>Ocular findings in metachromatic leukodystrophy. An electron microscopic and enzyme study in different clinical and genetic variants</article-title><source>Arch. Ophthalmol.</source><year>1979</year><volume>97</volume><fpage>1495</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.1001/archopht.1979.01020020157015</pub-id><pub-id pub-id-type="pmid">37822</pub-id>
</element-citation>
      </ref>
      <ref id="B144-jcm-13-05114">
        <label>144.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>S.Y.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.L.</given-names></name>
<name><surname>Xia</surname><given-names>K.</given-names></name>
<name><surname>Sun</surname><given-names>D.D.</given-names></name>
<name><surname>Ai</surname><given-names>W.L.</given-names></name>
<name><surname>Fu</surname><given-names>X.M.</given-names></name>
<name><surname>Ye</surname><given-names>Q.R.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report</article-title><source>Front. Neurol.</source><year>2022</year><volume>13</volume><elocation-id>1010150</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2022.1010150</pub-id><pub-id pub-id-type="pmid">36341094</pub-id>
</element-citation>
      </ref>
      <ref id="B145-jcm-13-05114">
        <label>145.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vujosevic</surname><given-names>S.</given-names></name>
<name><surname>Parra</surname><given-names>M.M.</given-names></name>
<name><surname>Hartnett</surname><given-names>M.E.</given-names></name>
<name><surname>O&#x2019;Toole</surname><given-names>L.</given-names></name>
<name><surname>Nuzzi</surname><given-names>A.</given-names></name>
<name><surname>Limoli</surname><given-names>C.</given-names></name>
<name><surname>Villani</surname><given-names>E.</given-names></name>
<name><surname>Nucci</surname><given-names>P.</given-names></name>
</person-group><article-title>Optical coherence tomography as retinal imaging biomarker of neuroinflammation/neurodegeneration in systemic disorders in adults and children</article-title><source>Eye</source><year>2022</year><volume>37</volume><fpage>203</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1038/s41433-022-02056-9</pub-id><pub-id pub-id-type="pmid">35428871</pub-id>
</element-citation>
      </ref>
      <ref id="B146-jcm-13-05114">
        <label>146.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van der Knaap</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Magnetic resonance in childhood white-matter disorders</article-title><source>Dev. Med. Child. Neurol.</source><year>2001</year><volume>43</volume><fpage>705</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1017/s001216220100127x</pub-id><pub-id pub-id-type="pmid">11665829</pub-id>
</element-citation>
      </ref>
      <ref id="B147-jcm-13-05114">
        <label>147.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheon</surname><given-names>J.E.</given-names></name>
<name><surname>Kim</surname><given-names>I.O.</given-names></name>
<name><surname>Hwang</surname><given-names>Y.S.</given-names></name>
<name><surname>Kim</surname><given-names>K.J.</given-names></name>
<name><surname>Wang</surname><given-names>K.C.</given-names></name>
<name><surname>Cho</surname><given-names>B.K.</given-names></name>
<name><surname>Chi</surname><given-names>J.G.</given-names></name>
<name><surname>Kim</surname><given-names>C.J.</given-names></name>
<name><surname>Kim</surname><given-names>W.S.</given-names></name>
<name><surname>Yeon</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Leukodystrophy in children: A pictorial review of MR imaging features</article-title><source>Radiographics</source><year>2002</year><volume>22</volume><fpage>461</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1148/radiographics.22.3.g02ma01461</pub-id><pub-id pub-id-type="pmid">12006681</pub-id>
</element-citation>
      </ref>
      <ref id="B148-jcm-13-05114">
        <label>148.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Imes</surname><given-names>R.K.</given-names></name>
<name><surname>Hoyt</surname><given-names>W.F.</given-names></name>
</person-group><article-title>Magnetic resonance imaging signs of optic nerve gliomas in neurofibromatosis 1</article-title><source>Am. J. Ophthalmol.</source><year>1991</year><volume>111</volume><fpage>729</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1016/S0002-9394(14)76780-7</pub-id><pub-id pub-id-type="pmid">1903904</pub-id>
</element-citation>
      </ref>
      <ref id="B149-jcm-13-05114">
        <label>149.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Viglianesi</surname><given-names>A.</given-names></name>
<name><surname>Messina</surname><given-names>M.</given-names></name>
<name><surname>Chiaramonte</surname><given-names>R.</given-names></name>
<name><surname>Meli</surname><given-names>G.A.</given-names></name>
<name><surname>Meli</surname><given-names>L.</given-names></name>
<name><surname>Chiaramonte</surname><given-names>I.</given-names></name>
<name><surname>Pero</surname><given-names>G.</given-names></name>
</person-group><article-title>An interpretation of optic nerve tortuosity. A case report</article-title><source>Neuroradiol. J.</source><year>2009</year><volume>22</volume><fpage>381</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1177/197140090902200403</pub-id><pub-id pub-id-type="pmid">24207141</pub-id>
</element-citation>
      </ref>
      <ref id="B150-jcm-13-05114">
        <label>150.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Misra</surname><given-names>M.</given-names></name>
<name><surname>Mohanty</surname><given-names>A.B.</given-names></name>
<name><surname>Rath</surname><given-names>S.</given-names></name>
</person-group><article-title>Giant aneurysm of internal carotid artery presenting features of retrobulbar neuritis</article-title><source>Indian J. Ophthalmol.</source><year>1991</year><volume>39</volume><fpage>28</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">1894342</pub-id>
</element-citation>
      </ref>
      <ref id="B151-jcm-13-05114">
        <label>151.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seiff</surname><given-names>S.R.</given-names></name>
<name><surname>Brodsky</surname><given-names>M.C.</given-names></name>
<name><surname>MacDonald</surname><given-names>G.</given-names></name>
<name><surname>Berg</surname><given-names>B.O.</given-names></name>
<name><surname>Howes</surname><given-names>E.L.</given-names><suffix>Jr.</suffix></name>
<name><surname>Hoyt</surname><given-names>W.F.</given-names></name>
</person-group><article-title>Orbital optic glioma in neurofibromatosis. Magnetic resonance diagnosis of perineural arachnoidal gliomatosis</article-title><source>Arch. Ophthalmol.</source><year>1987</year><volume>105</volume><fpage>1689</fpage><lpage>1692</lpage><pub-id pub-id-type="doi">10.1001/archopht.1987.01060120087032</pub-id><pub-id pub-id-type="pmid">3120679</pub-id>
</element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig position="float" id="jcm-13-05114-f001">
      <label>Figure 1</label>
      <caption>
        <p>PRISMA 2020 flow diagram. Source: [<xref rid="B134-jcm-13-05114" ref-type="bibr">134</xref>].</p>
      </caption>
      <graphic xlink:href="jcm-13-05114-g001" position="float"/>
    </fig>
    <fig position="float" id="jcm-13-05114-f002">
      <label>Figure 2</label>
      <caption>
        <p>Diagrammatic map revealing the OCT examination of a patient with metachromatic leukodystrophy, showing regular peripapillary retinal nerve fiber layer (RNFL) thickness in the right eye measured by spectral domain OCT (SD-OCT). (<bold>a</bold>) The appearance of the right optic nerve. (<bold>b</bold>) Transverse image of the RNFL. (<bold>c</bold>) Segmentation of the RNFL. Each area is colour coded to indicate whether the thickness of the nerve fiber layer is in the normal range (green) or out of range (yellow or red). (<bold>d</bold>) RNFL thickness map of the right eye. The different coloured areas in the background represent reference areas (normal distributions). The black line represents the measured thickness of the patient&#x2019;s nerve fiber layer. This curve can be used to recognize whether the thickness in certain areas is within (green area) or outside (red area) the normal range.</p>
      </caption>
      <graphic xlink:href="jcm-13-05114-g002" position="float"/>
    </fig>
    <fig position="float" id="jcm-13-05114-f003">
      <label>Figure 3</label>
      <caption>
        <p>Diagrammatic map revealing the OCT examination of a patient with Krabbe disease, showing superior RNFL thinning in the right eye. (<bold>a</bold>) The appearance of the right optic nerve. (<bold>b</bold>) Transverse image of the RNFL. (<bold>c</bold>) Segmentation of the RNFL. Each area is colour coded to indicate whether the thickness of the nerve fiber layer is in the normal range (green) or out of range (yellow or red). (<bold>d</bold>) RNFL thickness map of the right eye. The different coloured areas in the background represent reference areas (normal distributions). The black line represents the measured thickness of the patient&#x2019;s nerve fiber layer. This curve can be used to recognize whether the thickness in certain areas is within (green area) or outside (red area) the normal range.</p>
      </caption>
      <graphic xlink:href="jcm-13-05114-g003" position="float"/>
    </fig>
    <fig position="float" id="jcm-13-05114-f004">
      <label>Figure 4</label>
      <caption>
        <p>Pathological brain MRI findings of selected patients with myelin involvement of the visual pathway.</p>
      </caption>
      <graphic xlink:href="jcm-13-05114-g004" position="float"/>
    </fig>
    <fig position="float" id="jcm-13-05114-f005">
      <label>Figure 5</label>
      <caption>
        <p>Pathological findings of the optic nerves.</p>
      </caption>
      <graphic xlink:href="jcm-13-05114-g005" position="float"/>
    </fig>
    <table-wrap position="float" id="jcm-13-05114-t001">
      <object-id pub-id-type="pii">jcm-13-05114-t001_Table 1</object-id>
      <label>Table 1</label>
      <caption>
        <p>Occurrence of neuro-ophthalmologic symptoms, median age of onset of the disease, and patient sex in different leukodystrophy forms in the HLC and LLC.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sex </th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sex * </th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
          </tr>
          <tr>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disease</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> HLC (%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median AO in Months</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">m</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">f</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disease</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> LLC (%) *</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median AO in Months *</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">m</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">f</th>
          </tr>
          <tr>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">148/217 (68%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">128</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">831/1090 (76%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">655</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">219</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21/50 <break/>(42%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39/122 <break/>(32%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34/34 <break/>(100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29/35 <break/>(83%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14/25 <break/>(56%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47/86 <break/>(55%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X-ALD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/22<break/>(59%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X-ALD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32/47 <break/>(68%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PMD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/13 <break/>(100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PMD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">285/291 (98%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">254</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VWM</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/12 <break/>(58%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VWM</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/24 <break/>(29%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AxD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/10 <break/>(30%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AxD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/6 <break/>(67%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AGS</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/9 <break/>(67%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AGS</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/3 <break/>(67%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLC</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/5 <break/>(40%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLC</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 <break/>(100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27/37 <break/>(73%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">others</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">385/475 (81%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">253</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">138</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>HLC = Hamburg leukodystrophy cohort, LLC = literature leukodystrophy cohort, AO = age of onset of the disease, MLD = metachromatic leukodystrophy, CD = Canavan disease, KD = Krabbe disease, X-ALD = X-linked adrenoleukodystrophy, PMD = Pelizaeus&#x2013;Merzbacher disease, VWM = vanishing white matter disease, AxD = Alexander disease, AGS = Aicardi&#x2013;Gouti&#xE8;res syndrome, MLC = megalencephalic leukoencephalopathy with subcortical cysts, others = less frequent leukodystrophies. * Clinical data on the occurrence of neuro-ophthalmologic symptoms could be determined for 1090/1153 patients. Clinical data on sex could be determined for 874/1153 patients. Clinical data on age of onset of the disease could be determined for 654/1153 patients.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap position="float" id="jcm-13-05114-t002">
      <object-id pub-id-type="pii">jcm-13-05114-t002_Table 2</object-id>
      <label>Table 2</label>
      <caption>
        <p>Frequency of different neuro-ophthalmologic symptoms in leukodystrophy patients of the HLC and LLC related to the total number of pathologic findings.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> HLC (%)</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> LLC (%)</th>
          </tr>
          <tr>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total NOS</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">366</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1057</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EMD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">111/366 (30%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">637/1057 (60%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fixational eye movement</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55/366 (15%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24/1057 (2%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Posterior segment findings</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47/366 (13%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">145/1057 (18%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Refractive errors</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37/366 (10%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pathological light reflex</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36/366 (10%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28/1057 (3%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visual function</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23/366 (6%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">223/1057 (21%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anterior and periocular segment findings</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23/366 (6%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>HLC = Hamburg leukodystrophy cohort, LLC = literature leukodystrophy cohort, NOS = neuro-ophthalmologic symptom, EMD = eye movement disorders.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap position="float" id="jcm-13-05114-t003">
      <object-id pub-id-type="pii">jcm-13-05114-t003_Table 3</object-id>
      <label>Table 3</label>
      <caption>
        <p>Occurrence of specific neuro-ophthalmologic symptoms in absolute numbers and percentages in different leukodystrophies in the HLC and LLC.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nystagmus (EMD)</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Strabismus (EMD)</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FEMD</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Visual Function</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pathological Light Reflex</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
          </tr>
          <tr>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> HLC (%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> LLC (%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> HLC (%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> LLC (%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> HLC (%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> LLC (%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> HLC (%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> LLC (%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> HLC (%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> LLC (%)</th>
          </tr>
          <tr>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60/217 <break/>(28%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">569/790 (72%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40/217 <break/>(18%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68/202 <break/>(34%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55/217 <break/>(25%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24/35 <break/>(69%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23/217 <break/>(11%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">223/417 (53%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31/217 <break/>(14%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28/72 <break/>(39%)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PMD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/13 <break/>(100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">273/276 (99%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/13 <break/>(31%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/11 <break/>(27%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/13 <break/>(15%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 <break/>(100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/13 <break/>(0%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24/94 <break/>(26%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/13 <break/>(8%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21/34<break/>(62%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9/15 <break/>(60%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9/34 <break/>(26%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19/34<break/>(56%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/17<break/>(41%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/34<break/>(21%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14/14<break/>(100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/34<break/>(21%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1<break/>(100%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VWM</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/12 <break/>(25%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 <break/>(100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/12 <break/>(17%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/12<break/>(17%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/12<break/>(8%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1<break/>(100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/12<break/>(8%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1<break/>(100%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AGS</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/9 <break/>(22%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/3 <break/>(67%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/9 <break/>(22%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/9<break/>(44%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1<break/>(100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/9<break/>(0%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/9<break/>(33%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AxD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/10 <break/>(20%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/4 <break/>(100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/10 <break/>(0%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1<break/>(100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/10<break/>(0%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/10<break/>(0%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/10<break/>(10%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/25 <break/>(16%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/112 <break/>(12%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/25 <break/>(12%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/35<break/>(14%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/25<break/>(28%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/2<break/>(100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/25<break/>(8%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59/108<break/>(44%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/25<break/>(16%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20/34<break/>(59%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X-ALD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/22 <break/>(5%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/4 <break/>(100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/22 <break/>(23%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19/43<break/>(44%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/22<break/>(27%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/22<break/>(27%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36/57<break/>(63%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/22<break/>(5%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/50 <break/>(4%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/3 <break/>(100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/50 <break/>(10%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17/63<break/>(27%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/50<break/>(14%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/50<break/>(2%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11/50<break/>(22%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLC</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/5 <break/>(0%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/5 <break/>(0%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/5<break/>(0%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/5<break/>(0%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/5<break/>(0%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">others</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12/37 <break/>(32%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">260/372 (70%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10/37 <break/>(27%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23/49<break/>(47%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/37<break/>(19%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/14<break/>(93%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/37<break/>(16%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89/143<break/>(63%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/37<break/>(5%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/36<break/>(17%)</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>HLC = Hamburg leukodystrophy cohort, LLC = literature leukodystrophy cohort, EMD = eye movement disorder, FEMD = fixational deficit, MLD = metachromatic leukodystrophy, CD = Canavan disease, KD = Krabbe disease, X-ALD = X-linked adrenoleukodystrophy, PMD = Pelizaeus&#x2013;Merzbacher disease, VWM = vanishing white matter disease, AxD = Alexander disease, AGS = Aicardi&#x2013;Gouti&#xE8;res syndrome, MLC = megalencephalic leukoencephalopathy with subcortical cysts, others = less frequent leukodystrophies.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap position="float" id="jcm-13-05114-t004">
      <object-id pub-id-type="pii">jcm-13-05114-t004_Table 4</object-id>
      <label>Table 4</label>
      <caption>
        <p>Fraction of pathological VEP findings in patients with different leukodystrophies.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> HLC (%)</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic>/<italic toggle="yes">n</italic> LLC (%)</th>
          </tr>
          <tr>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35/54 (65%)</th>
            <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52/79 (66%)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PMD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/4 (100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/16 (81%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AGS</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 (100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLC</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/2 (100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/1 (100%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/5 (80%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3 (33%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11/19 (58%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9/12 (75%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VWM</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/4 (50%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">not specified</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X-ALD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/5 (40%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/5 (60%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AxD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/3 (33%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/2 (0%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KD</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/4 (25%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23/37 (62%)</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">others</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/7 (100%)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/3 (66%)</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>HLC = Hamburg leukodystrophy cohort, LLC = literature leukodystrophy cohort, PMD = Pelizaeus&#x2013;Merzbacher disease, AGS = Aicardi&#x2013;Gouti&#xE8;res syndrome, MLC = megalencephalic leukoencephalopathy with subcortical cysts, CD = Canavan disease, MLD = metachromatic leukodystrophy, VWM = vanishing white matter disease, X-ALD = X-linked adrenoleukodystrophy, AxD = Alexander disease, KD = Krabbe disease, others = less frequent leukodystrophies.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>